Triazolopyrimidone small molecule WRN inhibitor for MSI-H solid tumors

By developing novel WRN inhibitors, the limited efficacy of existing treatments for MSI-H tumors has been addressed, achieving effective treatment for WRN-mediated diseases, particularly various cancers.

CN119019407APending Publication Date: 2024-11-26SUZHOU PUHE BIOPHARMA CO LTD
View PDF 0 Cites 6 Cited by

Patent Information

Application Number
CN202411117426.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-03-18
Filing Date
2024-08-15
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Currently, there is a lack of effective WRN inhibitors to treat tumors with high microsatellite instability, such as colorectal cancer and gastric cancer. Existing immunotherapies have limited efficacy in MSI-H tumor patients, and new treatment methods are urgently needed.

Method used

A novel WRN inhibitor has been developed to target the WRN enzyme to induce cell cycle arrest and apoptosis in MSI-H tumor cells, including compounds with specific structures and their pharmaceutically acceptable salts, isotope variants, and stereoisomers.

Benefits of technology

This WRN inhibitor can effectively treat WRN-mediated diseases, such as various cancers, providing new possibilities for the treatment of MSI-H-related cancers and enhancing the therapeutic effect on tumors with high mutation rates.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004994037860000011
    Figure BDA0004994037860000011
  • Figure BDA0004994037860000061
    Figure BDA0004994037860000061
  • Figure BDA0004994037860000114
    Figure BDA0004994037860000114
Patent Text Reader

Abstract

The present invention provides a compound of formula (I) as a WRN inhibitor, a compound or a pharmaceutically acceptable salt, isotope variant, tautomer or stereoisomer thereof. The invention also provides a pharmaceutical composition comprising the compound, and its use in the treatment of cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention claims priority to Chinese patent application 2024103058050 filed on March 18, 2024. Technical Field

[0002] The present invention belongs to the field of medicine, and in particular relates to a WRN inhibitor. Background Art

[0003] Abnormal DNA mismatch repair (MMR) can lead to high mutations (deletions or insertions) in the DNA nucleotide repeat region, which is called microsatellite instability (MSI). High microsatellite instability (MSI-H) can induce tumors, including colorectal cancer, gastric cancer, endometrial cancer, and ovarian cancer (Nature, 2019, 568, 551-556), among which colorectal cancer (15%) and gastric cancer (22%) have the highest mutation rates. Although immunotherapy PD-1 / PD-L1 currently has very good therapeutic effects in multiple tumors, such as pembrolizumab, which greatly improves the median progression-free survival (PFS) in patients with MSI-H advanced colorectal cancer compared to chemotherapy, and has been approved by the FDA as a first-line therapy (N. Engl. J. Med. 2020, 383, 2207-2218), there are still many MSI-H tumor patients who cannot benefit from it. In addition, the 2022 ASCO conference reported that in the Phase 2 clinical CheckMate 142 (NCT02060188) trial: the dual immunotherapy PD-1+CTLA-4 (nivolumab+ipilimumab) was used to treat patients with metastatic colorectal cancer. Regardless of whether the patients were in first-line treatment or second-line treatment, more than half of the tumor patients would relapse after 4 years of follow-up, so new treatments are urgently needed.

[0004] Synthetic lethality means that in tumor cells, the inactivation of any single gene in the two genes has no obvious effect on the survival of tumor cells, but the simultaneous inactivation of the two genes can lead to the death of tumor cells (Nat. Rev. Drug Discov. 2020, 19 (1): 23-38, Cancer Discov. 2021, 11 (7): 1626-1635). Synthetic lethal targeted drugs generally produce a good therapeutic safety window, while also increasing the development accessibility of certain targets with high mutation rates but difficult to drug. At present, the most successful cases of synthetic lethality are PARP1 / 2 inhibitors such as Olaparib, Rucaparib, Niraparib, etc. These drugs have achieved excellent therapeutic effects in the treatment of BRCA1 / 2 mutant ovarian cancer, breast cancer, etc. and have been approved for marketing (Nat. Rev. Drug Discov. 2020, 19 (10): 711-736; Nat. Rev. Clin. Oncol. 2020, 17 (3): 136-137). In 2019, Adam J.Bass published consecutive articles in Nature proving that Werner helicase (WRN) is a synthetic lethal target for MSI-H tumors (Nature, 2019, 568, 551-556; Nature, 2019, 586, 292-298). Knocking out WRN as a whole or mutating WRN's helicase to K557M (loss of helicase function) both induce cell cycle arrest and apoptosis in MSI-H tumor cells. Not only that, Mathew J.Garnett et al. also found that even if the tumor cells of MSI-H patients become resistant after chemotherapy and immunotherapy, they can still further inhibit tumor growth by inhibiting WRN (Cancer Discov. 2021, 11, 1923-1937).

[0005] Although progress has been made in WRN research, there is still no WRN inhibitor that has entered the clinic to treat MSI-H related cancers. The novel WRN inhibitor provided by the present invention is expected to meet clinical needs. Summary of the invention

[0006] In one aspect, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof, and a mixture thereof:

[0007]

[0008] in,

[0009] X and Y are each independently selected from CH or N, and at least one of X and Y is a N atom;

[0010] Ring A is absent, or Ring A is selected from C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 5-10 membered heterocyclyl or C 6-10 Aryl;

[0011] R1 is selected from 5-12 membered heteroaryl or 5-12 membered heterocyclyl, wherein R1 is optionally substituted by 1, 2, 3, 4 or 5 R x replace;

[0012] Ring B is absent, or Ring B is selected from a 5-6 membered heteroaryl or a 5-7 membered heterocyclyl;

[0013] R x Selected from H, D, halogen, NH2, CN, OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, -C(O)R a 、-C(O)OR a 、-OC(O)R a 、-C(O)NH-R a 、-NHC(O)-R a 、-(CH2) p -OR a 、-(CH2) p -C(O)R a 、-P(O)-(R a )2 or -S(O)2-R a , where R a Selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl or C 3-6 Cycloalkyl, p is selected from 0, 1, 2, 3 or 4; or, two R on the same atom x Together they form oxo or thio;

[0014] R2 is selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 3-6 Cycloalkyl;

[0015] R3 is selected from H, D, halogen, NH2, CN, OH, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy or C 3-6 Cycloalkyl, or two R3 on different carbon atoms are connected to form a bridged ring, or two R3 on the same carbon atom are connected to form a C 3-10 Cycloalkyl, 5-10 membered heteroaryl, C 3-10Cycloalkyl or 3-10 membered heterocyclic group;

[0016] R4 is selected from H, D, halogen, NH2, CN, OH, SF5, SCF3, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Alkylthio, C 3-10 Cycloalkyl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl or C 6-10 Aryl;

[0017] R5 is selected from H, D, halogen, NH2, CN, OH, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 3-6 Cycloalkyl;

[0018] m is selected from 0, 1, 2, 3, 4 or 5;

[0019] n is selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8;

[0020] Indicates a single bond or a double bond;

[0021] R1-R5 may be optionally deuterated, up to fully deuterated.

[0022] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention, and optionally a pharmaceutically acceptable excipient.

[0023] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable excipient, which may also contain another therapeutic agent.

[0024] In another aspect, the present invention provides the use of a compound of the present invention in the preparation of a medicament for treating and / or preventing a WRN-mediated disease.

[0025] In another aspect, the present invention provides a method for treating and / or preventing a WRN-mediated disease in a subject, comprising administering to the subject a compound or composition of the present invention.

[0026] In another aspect, the present invention provides a compound of the present invention or a composition of the present invention for use in the treatment and / or prevention of a WRN-mediated disease.

[0027] In a specific embodiment, the diseases treated by the present invention include cancers selected from the group consisting of acoustic neuroma, adenocarcinoma, adrenal cancer, anal cancer, angiosarcoma (e.g., lymphangiosarcoma, lymphangioendothelioma, hemangioma), appendix cancer, benign monoclonal gamma disease, bile duct cancer, bladder cancer, brain cancer (e.g., meningioma, glioma, e.g., astrocytoma, oligodendroglioma, medulloblastoma), bronchial cancer, carcinoid tumor, cervical cancer (e.g., cervical adenocarcinoma), choriocarcinoma, chordoma, craniopharyngioma, colorectal cancer (e.g., colon cancer, rectal cancer, colorectal adenocarcinoma), epithelial cancer, ependymoma, endothelial sarcoma (e.g., Kaposi's sarcoma, multiple idiopathic hemorrhagic sarcoma), endometrial cancer (e.g., uterine cancer, uterine sarcoma), esophageal cancer (e.g., esophageal adenocarcinoma, Barrett's adenocarcinoma), Ewing's sarcoma, eye cancer (e.g., intraocular melanoma, retinoblastoma), hypereosinophilia, gallbladder cancer, gastric cancer (e.g., gastric adenocarcinoma), gastrointestinal stromal tumor (GIST), head and neck cancer (e.g., head and neck squamous cell carcinoma), oral cancer (e.g., oral squamous cell carcinoma), laryngeal cancer (e.g., laryngeal cancer, pharyngeal cancer, nasopharyngeal carcinoma, oropharyngeal cancer)), hematopoietic system cancer (e.g., leukemia, such as acute lymphoblastic leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), Acute myeloid leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myeloid leukemia (CML) (e.g., B-cell CML, T-cell CML), chronic lymphocytic leukemia (CLL) (e.g., B-cell CLL, T-cell CLL), follicular lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), marginal zone B-cell lymphoma (e.g., mucosa-associated lymphoid tissue (MALT) lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt lymphoma, lymphoma Plasma cell lymphoma, hairy cell leukemia (HCL), immunoblastic large cell lymphoma, precursor B lymphoblastic lymphoma and primary central nervous system (CNS) lymphoma; and T-cell non-Hodgkin lymphoma, such as precursor T lymphoblastic lymphoma / leukemia, peripheral T-cell lymphoma (such as cutaneous T-cell lymphoma (e.g., mycosis fungoides, Sezary syndrome), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathy-type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, anaplastic large cell lymphoma); mixtures of one or more of the above leukemias / lymphomas;Multiple myeloma (MM), heavy chain disease (e.g., alpha chain disease, gamma chain disease, mu chain disease), hemangioblastoma, inflammatory myofibroblastic tumor, immune cell amyloidosis, kidney cancer (e.g., Wilms tumor, renal cell carcinoma), liver cancer (e.g., hepatocellular carcinoma, malignant hepatocellular carcinoma), lung cancer (e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), lung adenocarcinoma, leiomyosarcoma (LMS), mastocytosis (e.g., systemic mastocytosis), myelodysplastic syndrome (MDS), mesothelioma, myeloproliferative disorders (MPD) (e.g., true Polycythemia vera (PV), essential thrombocythemia (ET), idiopathic myeloid metaplasia (AMM), chronic idiopathic myelofibrosis, chronic myeloid leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES), neuroblastoma, neurofibroma (such as type 1 or type 2 neurofibromatosis, neurothecoma), neuroendocrine cancer (such as gastroenteropancreatic neuroendocrine tumor (GEP-NET), carcinoid tumor), osteosarcoma, ovarian cancer (such as cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma), papillary adenocarcinoma, penile cancer. ;

[0028] Other objects and advantages of the present invention will be apparent to those skilled in the art from the following detailed description, examples and claims.

[0029] definition

[0030] Chemical Definition

[0031] Definitions of specific functional groups and chemical terms are described in more detail below.

[0032] When a numerical range is listed, it is intended to include every value and sub-range within the stated range. For example, "C 1-6 "Alkyl" includes C1, C2, C3, C4, C5, C6, C 1-6 , C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-5 , C 2-4 , C 2-3 , C 3-6 , C 3-5 , C 3-4 , C 4-6 , C 4-5 and C 5-6 alkyl.

[0033] “C 1-6 "Alkyl" refers to a straight or branched chain saturated hydrocarbon group having 1 to 6 carbon atoms. In some embodiments, C 1-4 Alkyl and C1-2 Alkyl groups are preferred. 1-6 Examples of alkyl groups include methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), isobutyl (C4), n-pentyl (C5), 3-pentyl (C5), pentyl (C5), neopentyl (C5), 3-methyl-2-butyl (C5), tert-pentyl (C5), and n-hexyl (C6). The term “C 1-6 "Alkyl" also includes heteroalkyl groups in which one or more (e.g., 1, 2, 3 or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus). The alkyl group may be optionally substituted by one or more substituents, for example, by 1 to 5 substituents, 1 to 3 substituents or 1 substituent. Conventional alkyl abbreviations include: Me(-CH3), Et(-CH2CH3), iPr(-CH(CH3)2), nPr(-CH2CH2CH3), n-Bu(-CH2CH2CH2CH3) or i-Bu(-CH2CH(CH3)2).

[0034] “C 2-6 "Alkenyl" refers to a straight or branched hydrocarbon group having 2 to 6 carbon atoms and at least one carbon-carbon double bond. In some embodiments, C 2-4 Alkenyl is preferred. 2-6 Examples of alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), pentenyl (C5), pentadienyl (C5), hexenyl (C6), and the like. The term “C 2-6 "Alkenyl" also includes heteroalkenyl groups in which one or more (e.g., 1, 2, 3 or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus). The alkenyl group may be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0035] “C 2-6 "Alkynyl" refers to a straight or branched chain hydrocarbon group having 2 to 6 carbon atoms, at least one carbon-carbon triple bond, and optionally one or more carbon-carbon double bonds. In some embodiments, C 2-4 Alkynyl is preferred. 2-6 Examples of alkynyl groups include, but are not limited to, ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), pentynyl (C5), hexynyl (C6), and the like. The term “C 2-6"Alkynyl" also includes heteroalkynyl groups, in which one or more (e.g., 1, 2, 3 or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus). Alkynyl groups may be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0036] “C 1-6 "Alkylene" refers to the removal of C 1-6 The other hydrogen of C alkyl forms a divalent group, and may be substituted or unsubstituted. 1-4 Alkylene, C 2-4 Alkylene and C 1-3 Alkylene is preferred. Unsubstituted alkylene includes, but is not limited to, methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), butylene (-CH2CH2CH2CH2-), pentylene (-CH2CH2CH2CH2CH2-), hexylene (-CH2CH2CH2CH2CH2CH2-), and the like. Exemplary substituted alkylenes, for example, alkylenes substituted with one or more alkyl (methyl) groups, include, but are not limited to, substituted methylene (-CH(CH3)-, -C(CH3)2-), substituted ethylene (-CH(CH3)CH2-, -CH2CH(CH3)-, -C(CH3)2CH2-, -CH2C(CH3) 2- ), substituted propylene (-CH(CH3)CH2CH2-, -CH2CH(CH3)CH2-, -CH2CH2CH(CH3)-, -C(CH3)2CH2CH2-, -CH2C(CH3)2CH2-, -CH2CH2C(CH3)2-), and the like.

[0037] “C 2-6 "Alkenylene" means removing the C 2-6 The divalent group is formed by the other hydrogen of the alkenyl group and may be substituted or unsubstituted. 2-4Alkenylene is particularly preferred. Exemplary unsubstituted alkenylene includes, but is not limited to, vinylene (-CH=CH-) and propenylene (e.g., -CH=CHCH2-, -CH2-CH=CH-). Exemplary substituted alkenylene, for example, alkenylene substituted with one or more alkyl (methyl) groups, includes, but is not limited to, substituted ethylene (-C(CH3)=CH-, -CH=C(CH3)-), substituted propenylene (-C(CH3)=CHCH2-, -CH=C(CH3)CH2-, -CH=CHCH(CH3)-, -CH=CHC(CH3)2-, -CH(CH3)-CH=CH-, -C(CH3)2-CH=CH-, -CH2-C(CH3)=CH-, -CH2-CH=C(CH3)-), and the like.

[0038] “C 2-6 "Alkynylidene" refers to the removal of C 2-6 The other hydrogen of the alkynyl group forms a divalent group, and may be substituted or unsubstituted. 2-4 Alkyne is particularly preferred. Exemplary alkynyl includes, but is not limited to, ethynyl (-C≡C-), substituted or unsubstituted propynyl (-C≡CCH2-), and the like.

[0039] "Halo" or "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br) and iodine (I).

[0040] Therefore, “C 1-6 "Haloalkyl" refers to the above-mentioned "C 1-6 "alkyl", which is substituted by one or more halogen groups. In some embodiments, C 1-4 Haloalkyl is particularly preferred, more preferably C 1-2 Haloalkyl. Exemplary haloalkyls include, but are not limited to, -CF3, -CH2F, -CHF2, -CHFCH2F, -CH2CHF2, -CF2CF3, -CCl3, -CH2Cl, -CHCl2, 2,2,2-trifluoro-1,1-dimethyl-ethyl, and the like. The haloalkyl group may be substituted at any available point of attachment, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0041] “C 1-6 "Alkoxy" refers to an -OR group, wherein R is a C 1-6 Alkyl. C 1-4 Alkoxy groups are preferred.

[0042] “C 1-6 "Haloalkoxy" refers to "C 1-6Alkoxy", which is substituted by one or more halogen groups. In some embodiments, C 1-4 Halogenated alkoxyalkyl is particularly preferred, more preferably C 1-2 Halogenated alkoxyalkyl.

[0043] “C 3-10 "Cycloalkyl" refers to a non-aromatic cyclic hydrocarbon group having 3 to 10 ring carbon atoms and zero heteroatoms. In some embodiments, C 4-10 Cycloalkyl, C 5-10 Cycloalkyl, C 4-7 Cycloalkyl, C 3-7 Cycloalkyl, C 3-6 Cycloalkyl, C 3-5 Cycloalkyl and C 3-4 Cycloalkyl is particularly preferred, more preferably C 5-6 Cycloalkyl. Cycloalkyl also includes a ring system in which the above-mentioned cycloalkyl ring is fused with one or more aryl or heteroaryl groups, wherein the connection point is on the cycloalkyl ring, and in such a case, the number of carbons continues to represent the number of carbons in the cycloalkyl system. Exemplary cycloalkyls include, but are not limited to, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), etc. The cycloalkyl group may be optionally substituted by one or more substituents, for example, substituted by 1 to 5 substituents, 1 to 3 substituents or 1 substituent.

[0044] "3-12 membered heterocyclyl" refers to a group of a 3- to 12-membered non-aromatic ring system having ring carbon atoms and 1 to 5 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus and silicon. In heterocyclyl groups containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom as long as the valence permits. In some embodiments, a 3-10 membered heterocyclyl is preferably a 3-10 membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms; in some embodiments, a 4-10 membered heterocyclyl is preferably a 4-10 membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms; in some embodiments, a 5-10 membered heterocyclyl is preferably a 5-10 membered non-aromatic ring system having ring carbon atoms and 1 to 5 ring heteroatoms; in some embodiments, a 5-8 membered heterocyclyl is preferably a 5-8 membered non-aromatic ring system having ring carbon atoms and 1 to 5 ring heteroatoms; in some embodiments, a 3-7 membered heterocyclyl is preferably a A 3- to 7-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms; preferably a 3- to 6-membered heterocyclyl, which is a 3- to 6-membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms; preferably a 4- to 7-membered heterocyclyl, which is a 4- to 7-membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms; preferably a 4- to 6-membered heterocyclyl, which is a 4- to 6-membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms; more preferably a 5- to 6-membered heterocyclyl, which is a 5- to 6-membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms; more preferably a 3- to 5-membered heterocyclyl, which is a 3- to 5-membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms. Heterocyclyl also includes bicyclic heterocyclyl, which refers to a ring system in which the above heterocyclyl ring is fused with one or more cycloalkyl groups, wherein the connection point is on the cycloalkyl ring, or a ring system in which the above heterocyclyl ring is fused with one or more aryl or heteroaryl groups, wherein the connection point is on the heterocyclyl ring; and in such a case, the number of ring members continues to represent the number of ring members in the heterocyclyl ring system. Exemplary 3-membered heterocyclyls containing one heteroatom include, but are not limited to, aziridine, oxirane, and thiorenyl. Exemplary 4-membered heterocyclyls containing one heteroatom include, but are not limited to, azetidine, oxirane, and thiorenyl. Exemplary 5-membered heterocyclyls containing one heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclic groups containing two heteroatoms include, but are not limited to, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-membered heterocyclic groups containing three heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl, and thiadiazolinyl.Exemplary 6-membered heterocyclic groups containing one heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclic groups containing two heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithianyl, dioxanyl. Exemplary 6-membered heterocyclic groups containing three heteroatoms include, but are not limited to, hexahydrotriazine (triazinanyl). Exemplary 7-membered heterocyclic groups containing one heteroatom include, but are not limited to, azepanyl, oxepane, and thianyl. Exemplary 5-membered heterocyclic groups fused to a C6 aryl ring (also referred to herein as 5,6-bicyclic heterocyclic groups) include, but are not limited to, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinone, and the like. Exemplary 6-membered heterocyclyl groups fused to a C6 aryl ring (also referred to herein as 6,6-bicyclic heterocyclyl groups) include, but are not limited to, tetrahydroquinolinyl, tetrahydroisoquinolinyl, tetrahydrobenzopyranyl, tetrahydropyranopyridinyl, etc. The heterocyclyl group may be optionally substituted with one or more substituents, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0045] “C 6-10 "Aryl" refers to a monocyclic or polycyclic (e.g., bicyclic) 4n+2 aromatic ring system (e.g., having 6 or 10 π electrons shared in a cyclic arrangement) having 6-10 ring carbon atoms and zero heteroatoms. In some embodiments, aryl has six ring carbon atoms ("C6 aryl"; e.g., phenyl). In some embodiments, aryl has ten ring carbon atoms ("C 10 Aryl also includes ring systems in which the above aryl ring is fused to one or more cycloalkyl or heterocyclyl groups, and the point of attachment is on the aryl ring, in which case the number of carbon atoms continues to refer to the number of carbon atoms in the aryl ring system. Aryl groups can be optionally substituted with one or more substituents, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0046] "5-14 membered heteroaryl" refers to a group of a 5-14 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in a cyclic arrangement) having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur. In heteroaryl groups containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom as long as the valence permits. Heteroaryl bicyclic ring systems may include one or more heteroatoms in one or both rings. Heteroaryl also includes bicyclic heteroaryl groups, which refer to a ring system in which the above-mentioned heteroaryl ring is fused to one or more cycloalkyl or heterocyclic groups, and the point of attachment is on the heteroaryl ring, in which case the number of carbon atoms continues to represent the number of carbon atoms in the heteroaryl ring system. In some embodiments, 5-12 membered heteroaryl groups are preferred, which are 5-12 membered monocyclic or bicyclic 4n+2 aromatic ring systems having ring carbon atoms and 1-4 ring heteroatoms. In some embodiments, 5-10 membered heteroaryls are preferred, which are 6-10 membered monocyclic or bicyclic 4n+2 aromatic ring systems with ring carbon atoms and 1-4 ring heteroatoms. In some embodiments, 5-9 membered heteroaryls are preferred, which are 5-9 membered monocyclic or bicyclic 4n+2 aromatic ring systems with ring carbon atoms and 1-4 ring heteroatoms. In other embodiments, 5-6 membered heteroaryls are particularly preferred, which are 5-6 membered monocyclic or bicyclic 4n+2 aromatic ring systems with ring carbon atoms and 1-4 ring heteroatoms. Exemplary 5-membered heteroaryls containing one heteroatom include, but are not limited to, pyrrolyl, furanyl, and thienyl. Exemplary 5-membered heteroaryls containing two heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, but are not limited to, triazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl) and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, but are not limited to, tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyridinyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, but are not limited to, pyridazinyl, pyrimidinyl and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, but are not limited to, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include, but are not limited to, azacycloheptatrienyl, oxacycloheptatrienyl and thiacycloheptatrienyl. Exemplary 5,6-bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzisothiazolyl, benzothiadiazolyl, indazinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, but are not limited to, naphthyridinyl, pteridinyl, quinolyl, isoquinolyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.A heteroaryl group can be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0047] "Cycloalkylene", "heterocyclylene", "arylene" or "heteroarylene" is a divalent group formed by removing another hydrogen from the above-defined "cycloalkyl", "heterocyclyl", "aryl" or "heteroaryl", and may be substituted or unsubstituted. For example, "C 5-7 "Cycloalkylene" refers to the removal of C 5-7 The "5- to 8-membered heterocyclylene" refers to a divalent group formed by removing another hydrogen atom of a 5- to 8-membered heterocyclyl. 6-10 "Arylene" refers to the removal of C 6-10 The "5-6 membered heteroarylene group" refers to a divalent group formed by removing another hydrogen atom of a 5-6 membered heteroaryl group.

[0048] Alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups and the like as defined herein are optionally substituted groups.

[0049] Exemplary substituents on carbon atoms include, but are not limited to, halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR aa 、-ON(R bb )2、-N(R bb )2、-N(R bb )3 + X-、-N(OR cc )R bb , -SH, -SR aa 、-SSR cc 、-C(=O)R aa 、-CO2H、-CHO、-C(OR cc 2. -CO2R aa 、-OC(=O)R aa 、-OCO2R aa 、-C(=O)N(R bb )2, -OC(=O)N(R bb )2.-NR bb C(=O)R aa 、-NR bb CO2R aa 、-NR bb C(=O)N(R bb )2, -C(=NR bb )R aa 、-C(=NR bb )OR aa 、-OC(=NRbb )R aa 、-OC(=NR bb )OR aa 、-C(=NR bb )N(R bb )2、-OC(=NR bb )N(R bb )2、-NR bb C(=NR bb )N(R bb )2、-C(=O)NR bb SO2R aa 、-NR bb SO2R aa 、-SO2N(R bb )2、-SO2R aa 、-SO2OR aa 、-OSO2R aa 、-S(=O)R aa 、-OS(=O)R aa 、-Si(R aa )3、-OSi(R aa )3、-C(=S)N(R bb )2、-C(=O)SR aa 、-C(=S)SR aa 、-SC(=S)SR aa 、-SC(=O)SR aa 、-OC(=O)SR aa 、-SC(=O)OR aa 、-SC(=O)R aa 、-P(=O)2R aa 、-OP(=O)2R aa 、-P(=O)(R aa )2、-OP(=O)(R aa )2、-OP(=O)(OR cc )2、-P(=O)2N(R bb )2、-OP(=O)2N(R bb )2、-P(=O)(NR bb )2、-OP(=O)(NR bb )2、-NR bb P(=O)(OR cc )2、-NR bb P(=O)(NR bb )2、-P(R cc )2、-P(R cc )3、-OP(R cc )2、-OP(Rcc )3. -B(R aa )2、-B(OR cc )2. -BR aa (OR cc ), alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is independently substituted by 0, 1, 2, 3, 4 or 5 R dd Group substitution;

[0050] Or the two geminal hydrogen atoms on the carbon atom are replaced by groups =O, =S, =NN (R bb )2, =NNR bb C(=O)R aa , =NNR bb C(=O)OR aa ,

[0051] =NNR bb S(=O)2R aa , =NR bb or = NOR cc replace;

[0052] R aa Each of R is independently selected from alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two R aa The groups are combined to form a heterocyclyl or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd Group substitution;

[0053] R bb Each of the following is independently selected from: hydrogen, -OH, -OR aa 、-N(R cc )2, -CN, -C(=O)R aa 、-C(=O)N(R cc 2. -CO2R aa 、-SO2R aa 、-C(=NR cc )OR aa 、-C(=NR cc )N(R cc )2、-SO2N(R cc 2. -SO2R cc 、-SO2OR cc 、-SOR aa 、-C(=S)N(R cc )2, -C(=O)SR cc 、-C(=S)SR cc、-P(=O)2R aa ,-P(=O)(R aa )2、-P(=O)2N(R cc )2, -P(=O)(NR cc )2, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two R bb The groups are combined to form a heterocyclyl or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd Group substitution;

[0054] R cc Each of R is independently selected from hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two R cc The groups are combined to form a heterocyclyl or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd Group substitution;

[0055] R dd Each of is independently selected from: halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR ee 、-ON(R ff )2、-N(R ff )2,-N(R ff )3 + X-、-N(OR ee )R ff , -SH, -SR ee 、-SSR ee 、-C(=O)R ee 、-CO2H、-CO2R ee 、-OC(=O)R ee 、-OCO2R ee 、-C(=O)N(R ff )2, -OC(=O)N(R ff )2.-NR ff C(=O)R ee 、-NR ff CO2R ee 、-NR ff C(=O)N(R ff )2, -C(=NR ff )OR ee 、-OC(=NR ff )R ee 、-OC(=NR ff )ORee 、-C(=NR ff )N(R ff )2, -OC(=NR ff )N(R ff )2.-NR ff C(=NR ff )N(R ff )2.-NR ff S02R ee 、-SO2N(R ff 2. -SO2R ee 、-SO2OR ee 、-OSO2R ee 、-S(=O)R ee 、-Si(R ee )3.-OSi(R ee )3. -C(=S)N(R ff )2, -C(=O)SR ee 、-C(=S)SR ee 、-SC(=S)SR ee 、-P(=O)2R ee ,-P(=O)(R ee )2.-OP(=O)(R ee )2.-OP(=O)(OR ee )2, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is independently substituted by 0, 1, 2, 3, 4 or 5 R gg group substitution, or two geminal R dd Substituents may combine to form =O or =S;

[0056] R ee Each of R is independently selected from alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is independently substituted by 0, 1, 2, 3, 4 or 5 R gg Group substitution;

[0057] R ff Each of R is independently selected from hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two R ff The groups are combined to form a heterocyclic or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R gg Group substitution;

[0058] R ggEach of is independently: halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OC 1-6 Alkyl, -ON(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)3 + X-、-NH(C 1-6 Alkyl)2 + X-、-NH2(C 1-6 alkyl) + X-、-NH3 + X-、-N(OC 1-6 Alkyl)(C 1-6 Alkyl), -N(OH)(C 1-6 Alkyl), -NH(OH), -SH, -SC 1-6 Alkyl, -SS(C 1-6 alkyl), -C(=O)(C 1-6 alkyl), -CO2H, -CO2(C 1-6 alkyl), -OC(=O)(C 1-6 Alkyl), -OCO2(C 1-6 alkyl), -C(=O)NH2, -C(=O)N(C 1-6 alkyl)2, -OC(=O)NH(C 1-6 alkyl), -NHC(=O)(C 1-6 Alkyl), -N(C 1-6 alkyl)C(=O)(C 1-6 Alkyl), -NHCO2(C 1-6 alkyl), -NHC(=O)N(C 1-6 Alkyl)2, -NHC(=O)NH(C 1-6 alkyl), -NHC(=O)NH2, -C(=NH)O(C 1-6 alkyl), -OC(=NH)(C 1-6 alkyl), -OC(=NH)OC 1-6 Alkyl, -C(=NH)N(C 1-6 Alkyl)2, -C(=NH)NH(C 1-6 alkyl), -C(=NH)NH2, -OC(=NH)N(C 1-6 Alkyl)2, -OC(NH)NH(C 1-6 alkyl), -OC(NH)NH2, -NHC(NH)N(C 1-6 Alkyl)2, -NHC(=NH)NH2, -NHSO2(C 1-6 Alkyl), -SO2N(C 1-6Alkyl)2, -SO2NH(C 1-6 Alkyl), -SO2NH2, -SO2C 1-6 Alkyl, -SO2OC 1-6 Alkyl, -OSO2C 1-6 Alkyl, -SOC 1-6 Alkyl, -Si(C 1-6 Alkyl)3, -OSi(C 1-6 Alkyl)3, -C(=S)N(C 1-6 alkyl)2, C(=S)NH(C 1-6 alkyl), C(=S)NH2, -C(=O)S(C 1-6 Alkyl), -C(=S)SC 1-6 Alkyl, -SC(=S)SC 1-6 Alkyl, -P(=O)2(C 1-6 alkyl), -P(=O)(C 1-6 Alkyl)2, -OP(=O)(C 1-6 Alkyl)2, -OP(=O)(OC 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C6-C 10 Aryl, C3-C7 heterocyclic, C5-C 10 heteroaryl; or two geminal R gg Substituents may combine to form =O or =S; wherein X - For the counter ion.

[0059] Exemplary substituents on nitrogen atoms include, but are not limited to, hydrogen, -OH, -OR aa 、-N(R cc )2, -CN, -C(=O)R aa 、-C(=O)N(R cc 2. -CO2R aa 、-SO2R aa 、-C(=NR bb )R aa 、-C(=NR cc )OR aa 、-C(=NR cc )N(R cc )2、-SO2N(R cc 2. -SO2R cc 、-SO2OR cc 、-SOR aa 、-C(=S)N(R cc )2, -C(=O)SR cc 、-C(=S)SRcc 、-P(=O)2R aa ,-P(=O)(R aa )2、-P(=O)2N(R cc )2, -P(=O)(NR cc )2, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two R attached to the nitrogen atom cc The groups are combined to form a heterocyclic or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd substituted with a group, and wherein R aa , R bb , R cc and R dd As mentioned above.

[0060] Other definitions

[0061] The term "pharmaceutically acceptable salt" as used herein refers to those carboxylates, amino acid addition salts of the compounds of the present invention which are suitable for use in contact with patient tissues within the scope of sound medical judgment, do not produce undue toxicity, irritation, allergic response, etc., are commensurate with a reasonable benefit / risk ratio, and are effective for their intended use, including (where possible) zwitterionic forms of the compounds of the present invention.

[0062] "Subjects" for administration include, but are not limited to, humans (i.e., males or females of any age group, e.g., pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults, or older adults)) and / or non-human animals, e.g., mammals, e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human animal. The terms "human," "patient," and "subject" are used interchangeably herein.

[0063] "Disease," "disorder," and "condition" are used interchangeably herein.

[0064] Generally, the "effective amount" of a compound refers to an amount sufficient to cause a target biological response. As will be appreciated by those of ordinary skill in the art, the effective amount of the compounds of the invention may vary depending on factors such as the biological target, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the age, health, and symptoms of the subject. An effective amount includes a therapeutically effective amount and a prophylactically effective amount.

[0065] "Combination" and related terms refer to the simultaneous or sequential administration of the compounds of the invention and other therapeutic agents. For example, the compounds of the invention can be administered simultaneously or sequentially with the other therapeutic agents in separate unit dosage forms, or can be administered simultaneously with the other therapeutic agents in a single unit dosage form. Specific implementation plan

[0066] As used herein, "compounds of the present invention" refers to compounds of the following formula (I) (including sub-general formulae, such as formula (II), (II-1), (III), (III-1), (IV), (IV-1), (V), (V-1), etc.), pharmaceutically acceptable salts, enantiomers, diastereomers, solvates, hydrates or isotopic variants thereof, and mixtures thereof.

[0067] In one embodiment, the present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof, and a mixture thereof:

[0068]

[0069] in,

[0070] X and Y are each independently selected from CH or N, and at least one of X and Y is a N atom;

[0071] Ring A is absent, or Ring A is selected from C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 5-10 membered heterocyclyl or C 6-10 Aryl;

[0072] R1 is selected from 5-12 membered heteroaryl or 5-12 membered heterocyclyl, wherein R1 is optionally substituted by 1, 2, 3, 4 or 5 R x replace;

[0073] Ring B is absent, or Ring B is selected from a 5-6 membered heteroaryl or a 5-7 membered heterocyclyl;

[0074] R x Selected from H, D, halogen, NH2, CN, OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, -C(O)R a 、-C(O)OR a 、-OC(O)R a 、-C(O)NH-R a 、-NHC(O)-R a 、-(CH2) p -OR a 、-(CH2) p -C(O)R a、-P(O)-(R a )2 or -S(O)2-R a , where R a Selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl or C 3-6 Cycloalkyl, p is selected from 0, 1, 2, 3 or 4; or, two R on the same atom x Together they form oxo or thio;

[0075] R2 is selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 3-6 Cycloalkyl;

[0076] R3 is selected from H, D, halogen, NH2, CN, OH, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy or C 3-6 Cycloalkyl, or two R3 on different carbon atoms are connected to form a bridged ring, or two R3 on the same carbon atom are connected to form a C 3-10 Cycloalkyl, 5-10 membered heteroaryl, C 3-10 Cycloalkyl or 3-10 membered heterocyclic group;

[0077] R4 is selected from H, D, halogen, NH2, CN, OH, SF5, SCF3, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Alkylthio, C 3-10 Cycloalkyl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl or C 6-10 Aryl;

[0078] R5 is selected from H, D, halogen, NH2, CN, OH, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 3-6 Cycloalkyl;

[0079] m is selected from 0, 1, 2, 3, 4 or 5;

[0080] n is selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8;

[0081] Indicates a single bond or a double bond;

[0082] R1-R5 may be optionally deuterated, up to fully deuterated.

[0083] X and Y

[0084] In one embodiment, X is CH; in another embodiment, X is N.

[0085] In one embodiment, Y is CH; in another embodiment, Y is N.

[0086] In one embodiment, at least one of X and Y is a N atom.

[0087] Ring A

[0088] In one embodiment, Ring A is absent; in another embodiment, Ring A is C 3-10 In another embodiment, ring A is a 5-10 membered heteroaryl, such as a 5-8 membered heteroaryl; In another embodiment, ring A is a 5-10 membered heterocyclyl, such as a 5-7 membered heterocyclyl; In another embodiment, ring A is C 6-10 Aryl.

[0089] In a specific embodiment, ring A is a 5-6 membered heteroaryl; in another embodiment, ring A and the benzene ring to which it is connected together form In another embodiment, Ring A and the benzene ring to which it is attached together form In another embodiment, Ring A and the benzene ring to which it is attached together form

[0090] Ring B

[0091] In one embodiment, Ring B is absent; in another embodiment, Ring B is C 3-10 In another embodiment, ring B is a 5-10 membered heteroaryl, such as a 5-8 membered heteroaryl; In another embodiment, ring B is a 5-10 membered heterocyclyl, such as a 5-7 membered heterocyclyl; In another embodiment, ring B is C 6-10 Aryl.

[0092] In one embodiment, the ring B is optionally substituted by 1, 2, 3, 4 or 5 selected from halogen, C 1-6 Alkyl or C 1-6 The substituents of the haloalkyl group are substituted.

[0093] R1

[0094] In one embodiment, R1 is 5-12 membered heteroaryl, such as 5-10 membered heteroaryl; in another embodiment, R1 is 5-12 membered heterocyclyl.

[0095] In one embodiment, R1 is a 5-12 membered bicyclic heteroaryl, such as a 5-10 membered bicyclic heteroaryl; in another embodiment, R1 is a 5-12 membered bicyclic heterocyclyl, such as a 5-10 membered bicyclic heterocyclyl.

[0096] In one embodiment, R1 is optionally replaced by 1, 2, 3, 4 or 5 R x replace.

[0097] In a specific embodiment, R1 is In another specific embodiment, R1 is In another specific embodiment, R1 is In another specific embodiment, R1 is In another specific embodiment, R1 is In another specific embodiment, R1 is In another specific embodiment, R1 is In another specific embodiment, R1 is In another specific embodiment, R1 is

[0098] In another specific embodiment, R1 is In another specific embodiment, R1 is In another specific embodiment, R1 is

[0099] In a preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is In another preferred embodiment, R1 is

[0100] In one embodiment, R1 may be optionally deuterated, up to fully deuterated.

[0101] R2

[0102] In one embodiment, R2 is H; in another embodiment, R2 is D; in another embodiment, R2 is halogen; in another embodiment, R2 is C 1-6 Alkyl groups, such as C 1-4 Alkyl; in another embodiment, R2 is C 1-6 haloalkyl; in another embodiment, R2 is C 1-6 Alkoxy; in another embodiment, R2 is C 1-6 In another embodiment, R2 is C 3-6 Cycloalkyl.

[0103] In one specific embodiment, R2 is H; in another specific embodiment, R2 is CH3; in another specific embodiment, R2 is CH2CH3; in another specific embodiment, R2 is trifluoroethyl; in another specific embodiment, R2 is methoxy; in another specific embodiment, R2 is cyclopropyl.

[0104] In one embodiment, R2 may be optionally deuterated, up to fully deuterated.

[0105] R3

[0106] In one embodiment, R3 is H; in another embodiment, R3 is D; in another embodiment, R3 is halogen; in another embodiment, R3 is NH2; in another embodiment, R3 is CN; in another embodiment, R3 is OH; in another embodiment, R3 is C 1-6 Alkyl; in another embodiment, R3 is C 1-4 Alkyl; in another embodiment, R3 is C 1-6 haloalkyl; in another embodiment, R3 is C 1-6 Alkoxy; in another embodiment, R3 is C 3-6 In another embodiment, two R3 are connected to the carbon atoms where they are located to form a 3-6 membered spiro ring or a bridged ring; in another embodiment, R3 on two different carbon atoms are connected to form a bridged ring; in another embodiment, two R3 on the same carbon atom are connected to form a C 3-10 Cycloalkyl, such as C 3-7 Cycloalkyl, such as C 3-5 In another embodiment, two R3 on the same carbon atom are linked to form a 5-10 membered heteroaryl; In another embodiment, two R3 on the same carbon atom are linked to form a C 3-10 Cycloalkyl, such as cyclopropyl, cyclobutyl; in another embodiment, two R3 on the same carbon atom are linked to form a 3-10 membered heterocyclic group.

[0107] In one specific embodiment, R3 is H; in another specific embodiment, R3 is D; in another embodiment, R3 is halogen, such as F, Cl or Br; in another embodiment, R3 is CN; in another embodiment, R3 is methyl; in another embodiment, R3 is ethyl; in another embodiment, R3 is trifluoromethyl; in another embodiment, R3 is cyclopropyl; in another embodiment, two R3 on the same carbon atom are connected to form cyclopropyl or cyclobutyl.

[0108] In one embodiment, R3 may be optionally deuterated, up to fully deuterated.

[0109] R4

[0110] In one embodiment, R4 is H; in another embodiment, R4 is D; in another embodiment, R4 is halogen, such as F, Cl or Br; in another embodiment, R4 is NH2; in another embodiment, R4 is CN; in another embodiment, R4 is OH; in another embodiment, R4 is SF5; in another embodiment, R4 is SCF3; in another embodiment, R4 is C 1-6 Alkyl; in another embodiment, R4 is C 1-6 haloalkyl, such as methyl and ethyl; in another embodiment, R4 is C 1-4 Alkyl; in another embodiment, R4 is C 1-6 haloalkyl, such as trifluoromethyl, difluoromethyl; in another embodiment, R4 is C 1-6 Alkoxy; in another embodiment, R4 is C 1-6 haloalkoxy, such as OCF3; in another embodiment, R4 is C 1-6 Alkylthio, such as methylthio and ethylthio; in another embodiment, R4 is C 3-10 Cycloalkyl, such as cyclopropyl; in another embodiment, R4 is C 3-6 In another embodiment, R4 is a 3-10 membered heterocyclyl; in another embodiment, R4 is a 4-10 membered heterocyclyl; in another embodiment, R4 is a 5-10 membered heteroaryl, such as pyridine; in another embodiment, R4 is C 6-10 Aryl.

[0111] In one embodiment, R4 may be optionally deuterated, up to fully deuterated.

[0112] R 4a , R 4b and R 4d

[0113] In one embodiment, R 4a is H; in another embodiment, R 4a is halogen, such as F; in another embodiment, R 4a is CN; in another embodiment, R 4a C 1-6 Alkyl; in another embodiment, R 4a C 1-6 Alkoxy; in another embodiment, R 4a C 1-6 Halogenated alkyl.

[0114] In one embodiment, R 4b is halogen, such as Cl, Br; in another embodiment, R4b is CN; in another embodiment, R 4b C 1-6 Alkyl, preferably C 1-4 Alkyl, such as CH2CH3; in another embodiment, R 4b C 1-6 Alkoxy; in another embodiment, R 4b C 1-6 Halogenated alkyl, preferably C 1-4 Haloalkyl, such as CF3.

[0115] In one embodiment, R 4d is H; in another embodiment, R 4d is CN; in another embodiment, R 4d is halogen, such as F, Cl; in another embodiment, R 4d C 1-6 Alkyl; in another embodiment, R 4d C 1-4 Alkyl, preferably C 1-2 Alkyl, such as CH3; in another embodiment, R 4d C 1-6 Alkoxy; in another embodiment, R 4d C 1-6 Halogenated alkyl.

[0116] R5

[0117] In one embodiment, R5 is H; in another embodiment, R5 is D; in another embodiment, R5 is halogen; in another embodiment, R5 is NH2; in another embodiment, R5 is CN; in another embodiment, R5 is OH; in another embodiment, R5 is C 1-6 Alkyl, preferably C 1-4 Alkyl, such as methyl, ethyl; in another embodiment, R5 is C 1-6 deuterated alkyl, such as CD3; in another embodiment, R5 is C 1-6 haloalkyl, such as trifluoromethyl; in another embodiment, R5 is C 1-6 Alkoxy, such as methoxy, ethoxy; in another embodiment, R5 is C 1-6 Alkylthio, such as methylthio; in another embodiment, R5 is C 3-6 Cycloalkyl, for example cyclopropyl.

[0118] In one embodiment, R5 may be optionally deuterated, up to fully deuterated.

[0119]

[0120] In one embodiment, represents a single bond; in another embodiment, represents a double bond; in another embodiment, Q is N and ring B is present, Indicates a single bond.

[0121] R x

[0122] In one embodiment, R x is H; in another embodiment, R x is D; in another embodiment, R x is halogen; in another embodiment, R x is NH2; in another embodiment, R x is CN; in another embodiment, R x is OH; in another embodiment, R x C 1-6 Alkyl; in another embodiment, R x C 1-4 Alkyl, for example; in another embodiment, R x C 1-6 Alkoxy; in another embodiment, R x C 1-6 haloalkyl; in another embodiment, R x -C(O)R a In another embodiment, R x -C(O)OR a In another embodiment, R x -OC(O)R a In another embodiment, R x -C(O)NH-R a In another embodiment, R x -NHC(O)-R a In another embodiment, R x -(CH2) p -OR a In another embodiment, R x -(CH2) p -C(O)R a In another embodiment, R x -P(O)-(R a )2; In another embodiment, R x -S(O)2-R a In another embodiment, two R on the same atomx together to form oxo; in another embodiment, two R x Together they form thio.

[0123] In a specific embodiment, R x is H; in another specific embodiment, R x is NH2; in another specific embodiment, R x is CH2OH; in another specific embodiment, R x is CH2OCH3; in another specific embodiment, R x is C(O)CH3; in another specific embodiment, R x is -S(O)2-CH3; in another specific embodiment, two R x Together they form an oxo group.

[0124] R y

[0125] In one embodiment, R y is H; in another embodiment, R y is D; in another embodiment, R y is halogen; in another embodiment, R y C 1-6 Alkyl; in another embodiment, R y C 1-6 Halogenated alkyl.

[0126] Q and Q'

[0127] In one embodiment, Q is CH; in another embodiment, Q is N.

[0128] In one embodiment, Q' is CH; in another embodiment, Q' is N.

[0129] In one embodiment, at most one of Q and Q' is N.

[0130] R a

[0131] In one embodiment, R a is H; in another embodiment, R a C 1-6 Alkyl, such as CH3; in another embodiment, R a C 1-6 haloalkyl; in another embodiment, R a C 3-6 Cycloalkyl.

[0132] m, n, k, and p

[0133] In one embodiment, m is selected from 0, 1, 2, 3, 4 or 5.

[0134] In one embodiment, n is selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8.

[0135] In one embodiment, k is selected from 0, 1, 2, 3, 4 or 5.

[0136] In one embodiment, p is selected from 0, 1, 2, 3 or 4.

[0137] Any technical solution or any combination thereof in any of the above specific embodiments can be combined with any technical solution or any combination thereof in other specific embodiments. For example, any technical solution or any combination thereof of ring A can be combined with ring B, X, Y, L, R1, R2, R3, R4, R 4a , R 4b , R 4d , R5, R x , R y ,Q,Q',R a The present invention is intended to include combinations of all these technical solutions, which are not listed one by one due to space limitations.

[0138] In a more specific embodiment, the present invention provides a compound of formula (I) as above, or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof, and a mixture thereof, wherein:

[0139] X and Y are each independently selected from CH or N, and at least one of X and Y is a N atom;

[0140] Ring A is absent or is selected from a 5-6 membered heteroaryl group, wherein the 5-6 membered heteroaryl group and the benzene ring to which it is connected together form the following heteroaryl group, The ring A is preferably absent;

[0141] R1 is a 5-10 membered heteroaryl group, said R1 is optionally substituted by 1, 2 or 3 R x replace;

[0142] R x Preferably, H, NH2, CH3, CH2OH, CH2OCH3 or C(O)CH3 or -S(O)2-CH3, or two R on the same carbon atom x Together they form an oxo group;

[0143] Preferably, R1 is selected from

[0144] Ring B is absent or selected from C 3-10 Cycloalkyl, 5-10 membered heterocyclyl, 5-10 membered heteroaryl or C 6-10 Aryl, the ring B is optionally substituted by 1, 2, 3, 4 or 5 selected from halogen, C 1-6 Alkyl or C 1-6 Substitution of haloalkyl groups;

[0145] Q and Q' are independently selected from CH or N, and at most one of Q and Q' is N;

[0146] R y Selected from H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0147] R2 is selected from C 1-4 Alkyl, such as CH3 or CH2CH3;

[0148] R3 is selected from H, D or C 1-4 Alkyl, such as H, D or CH3, or two R3 on different carbon atoms are connected to form a bridged ring, or two R3 on the same carbon atom are connected to form a C 3-5 Cycloalkyl, such as cyclopropyl;

[0149] R4 is selected from H, F, Cl, Br, CH3, CH2CH3, SCF3, OCF3, CF3 or pyridine;

[0150] R5 is selected from H, CH3 or CD3, preferably H or CH3;

[0151] R a Selected from C 1-6 alkyl;

[0152] m is selected from 0, 1, 2 or 3;

[0153] k is selected from 0, 1, 2, 3, 4 or 5.

[0154] In a more specific embodiment, the present invention provides a compound of the above formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof, and a mixture thereof, wherein R1 is selected from:

[0155] in,

[0156] represents a single bond or a double bond. When Q is N and ring B exists, represents a single bond;

[0157] Q and Q' are independently selected from CH or N, and at most one of Q and Q' is N;

[0158] Ring B is absent or selected from C 3-10 Cycloalkyl, 5-10 membered heterocyclyl, 5-10 membered heteroaryl or C 6-10 Aryl, the ring B is optionally substituted by 1, 2, 3, 4 or 5 selected from halogen, C 1-6 Alkyl or C 1-6 Substitution of haloalkyl groups;

[0159] R x Selected from H, NH2, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -C(O)R a 、-C(O)OR a 、-OC(O)R a 、-C(O)NH-R a 、-NHC(O)-R a 、-(CH2) p -OR a or -(CH2) p -C(O)R a , where R a Selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl, p is selected from 1, 2 or 3;

[0160] R y Selected from H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0161] R a Selected from C 1-6 alkyl;

[0162] m is selected from 0, 1, 2, 3, 4 or 5;

[0163] k is selected from 0, 1, 2, 3, 4 or 5;

[0164] Preferably,

[0165] represents a single bond or a double bond. When Q is N and ring B exists, Represents a single bond;

[0166] Q and Q' are independently selected from CH or N, and at most one of Q and Q' is N;

[0167] Ring B is absent or is selected from 5-7 membered heterocyclyl or 5-6 membered heteroaryl, and the ring B is optionally substituted by 1, 2 or 3 selected from halogen or C 1-4Substitution of alkyl groups;

[0168] R x Selected from H, NH2, C 1-4 Alkyl, -C(O)R a or -(CH2) p -OR a , where R a Select from H or C 1-4 Alkyl, p is selected from 1 or 2; R x Preferably H, NH2, CH3, CH2OH, CH2OCH3 or C(O)CH3;

[0169] R y Selected from H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0170] R a Selected from CH3;

[0171] m is selected from 0, 1, 2 or 3;

[0172] k is selected from 0, 1, 2 or 3;

[0173] More preferably,

[0174] R1 is selected from:

[0175] In a more specific embodiment, the present invention provides a compound of formula (I) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof, and a mixture thereof, which is selected from the following structures:

[0176]

[0177] in,

[0178] The variables are as defined herein.

[0179] In a more specific embodiment, the present invention provides a compound of formula (II-1) or (IIII-1), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof, and a mixture thereof:

[0180] In a more specific embodiment, the present invention provides a compound of the above formula (IV-1) or (V-1), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof, and a mixture thereof, wherein:

[0181] Ring A is absent or is selected from 5-10 membered heteroaryl, 5-10 membered heterocyclyl or C 6-10 Aryl;

[0182] X is selected from CH or N;

[0183] R x Selected from H, C 1-6 Alkyl, C 1-6 Alkoxy or C 1-6 Haloalkyl;

[0184] R2 is selected from C 1-6 Alkyl or C 1-6 Haloalkyl;

[0185] R3 is selected from H, D, C 1-6 Alkyl or C 1-6 A halogenated alkyl group, or two R3 groups on different carbon atoms are connected to form a bridged ring, or two R3 groups on the same carbon atom are connected to form a C 3-10 Cycloalkyl or 3-10 membered heterocyclic group;

[0186] R4 is selected from H, halogen, CN, SCF3, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl or C 1-6 Haloalkoxy;

[0187] R5 is selected from H, C 1-6 Alkyl, C 1-6 Alkoxy or C 1-6 Haloalkyl;

[0188] m is selected from 0, 1, 2, 3, 4 or 5;

[0189] n is selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8.

[0190] In a more specific embodiment, the present invention provides a compound of the above formula (IV-6) or (IV-7), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof, and a mixture thereof, wherein:

[0191] Ring A is absent;

[0192] X is selected from CH or N;

[0193] R x Select from H or C 1-6 alkyl;

[0194] R2 is selected from C 1-6 alkyl;

[0195] R3 is selected from H, D or C 1-6 Alkyl, or two R3 on different carbon atoms are connected to form a bridged ring, or two R3 on the same carbon atom are connected to form a C3-7 Cycloalkyl;

[0196] R4 is selected from H, halogen, SCF3, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl or C 1-6 Haloalkoxy;

[0197] R5 is selected from H or C 1-6 alkyl;

[0198] m is selected from 0, 1, 2, 3 or 4;

[0199] n is selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8.

[0200] In one embodiment, the present invention provides a compound of formula (I) as above, or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof, and a mixture thereof, wherein:

[0201] X and Y are each independently selected from CH or N, and at least one of X and Y is a N atom;

[0202] Ring B is present or absent, and is selected from a 5-6 membered heteroaryl group or a 5-6 membered heterocyclic group;

[0203] X1 and X2 are each independently selected from CH or N, represents a single or double bond;

[0204] Q is selected from CH or N;

[0205] R2 is selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 3-6 Cycloalkyl;

[0206] R3 is independently selected from H, halogen, CN, methyl, ethyl, trifluoromethyl or cyclopropyl;

[0207] R4 is independently selected from H, halogen, CN, SF5, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkylthio, C 3-6 Cycloalkyl or 4-10 membered heterocyclic group;

[0208] Ring A is present or absent, and ring A is selected from a 5-6 membered heteroaryl group or a 5-7 membered heterocyclic group;

[0209] R5 is selected from H, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, methylthio or cyclopropyl;

[0210] R x Selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, CN, NH2, -C(O)R a 、-C(O)OR a 、-(CH2) p -OR a 、-P(O)-(R a )2 or -S(O)2-R a ;

[0211] R a Select from H or C 1-6 alkyl;

[0212] m is selected from 0, 1, 2 or 3;

[0213] n is selected from 0, 1 or 2;

[0214] p is selected from 0, 1 or 2.

[0215] In another more specific embodiment, the present invention relates to the above-mentioned compound of formula (IV-1), formula (IV-2), formula (IV-3), formula (IV-4), formula (IV-5), formula (IV-6) or formula (V-1), or a pharmaceutically acceptable salt, isotopic variant, tautomer, or stereoisomer thereof:

[0216] in,

[0217] X is selected from CH or N;

[0218] Z is selected from O or NH, represents a single or double bond;

[0219] Q is selected from CH or N;

[0220] R2 is selected from H, methyl, ethyl, trifluoroethyl, methoxy or cyclopropyl;

[0221] R3 is independently selected from H, F, CN, methyl, ethyl, trifluoromethyl or cycloalkyl; or two R3 are connected to the carbon atom where they are located to form a cycloalkyl or cyclobutyl group;

[0222] R4 is independently selected from H, F, Cl, Br, CN, SF5, methyl, ethyl, trifluoromethyl, difluoromethyl, methylthio, ethylthio or cyclopropyl;

[0223] Ring A is present or absent, and ring A is selected from a 5-6 membered heteroaryl group or a 5-7 membered heterocyclic group;

[0224] R5 is selected from H, methyl, ethyl, trifluoromethyl, methoxy, methylthio or cyclopropyl;

[0225] R x Selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, CN, NH2, -C(O)R a 、-C(O)OR a 、-(CH2) p -OR a 、-P(O)-(R a )2 or -S(O)2-R a ;

[0226] R a Selected from H, C 1-6 Alkyl or C 3-6 Cycloalkyl;

[0227] m is selected from 0, 1, 2 or 3;

[0228] n is selected from 0, 1 or 2;

[0229] p is selected from 0, 1 or 2.

[0230] In another embodiment, the present invention relates to the following compound or its tautomer, stereoisomer or pharmaceutically acceptable salt, wherein the compound is selected from:

[0231]

[0232]

[0233]

[0234]

[0235] In another embodiment, the present invention relates to the following compound, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer thereof, wherein the compound is selected from:

[0236]

[0237] The compounds of the present invention may include one or more asymmetric centers and may therefore exist in a variety of stereoisomeric forms, for example, enantiomers and / or diastereoisomeric forms. For example, the compounds of the present invention may be individual enantiomers, diastereomers or geometric isomers (e.g., cis and trans isomers), or may be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomers. Isomers may be separated from the mixture by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers may be prepared by asymmetric synthesis.

[0238] The compounds of the present invention may also exist as tautomers. For compounds that exist in different tautomeric forms, a compound is not limited to any specific tautomer, but is intended to encompass all tautomeric forms.

[0239] The present invention also includes isotopically labeled compounds (isotopic variants) which are identical to those described by formula (A) but in which one or more atoms are replaced by atoms having an atomic mass or mass number different from the atomic mass or mass number commonly found in nature. Examples of isotopes that can be introduced into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, for example 2 H. 3 H. 13 C. 11 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 Cl. Compounds of the present invention containing the above isotopes and / or other isotopes of other atoms, their prodrugs and pharmaceutically acceptable salts of the compounds or prodrugs are within the scope of the present invention. Certain isotopically labeled compounds of the present invention, such as those in which a radioactive isotope (e.g. 3 H and 14 C) can be used for drug and / or substrate tissue distribution assays. 3 H and carbon-14, i.e. 14 C isotopes are particularly preferred because they are easy to prepare and detect. 2H, because higher metabolic stability can provide therapeutic benefits, such as prolonged half-life in vivo or reduced dosage requirements, and thus may be preferred in some cases. Isotope-labeled compounds of formula (A) of the present invention and their prodrugs can generally be prepared by replacing non-isotope-labeled reagents with readily available isotope-labeled reagents when carrying out the processes disclosed in the following schemes and / or Examples and Preparation Examples.

[0240] Pharmaceutical compositions and kits

[0241] On the other hand, the present invention provides a pharmaceutical composition comprising a compound of the present invention (also referred to as an "active ingredient") and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises an effective amount of a compound of the present invention. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound of the present invention. In some embodiments, the pharmaceutical composition comprises a preventive effective amount of a compound of the present invention.

[0242] The pharmaceutically acceptable excipient used in the present invention refers to a non-toxic carrier, adjuvant or vehicle that does not destroy the pharmacological activity of the compound formulated together. Pharmaceutically acceptable carriers, adjuvants or vehicles that can be used in the composition of the present invention include (but are not limited to) ion exchangers, aluminum oxide, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffer substances (such as phosphates), glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes (such as protamine sulfate), disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, silica gel, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and lanolin.

[0243] The present invention also includes a kit (e.g., a pharmaceutical package). The kit provided may include a compound of the invention, other therapeutic agents, and a first and second container (e.g., a vial, an ampoule, a bottle, a syringe, and / or a dispersible package or other suitable container) containing the compound of the invention and other therapeutic agents. In some embodiments, the kit provided may also optionally include a third container containing a pharmaceutical excipient for diluting or suspending the compound of the invention and / or other therapeutic agents. In some embodiments, the compound of the invention and other therapeutic agents provided in the first container and the second container are combined to form a unit dosage form.

[0244] Drug administration

[0245] Pharmaceutical composition provided by the invention can be administered by many ways, including but not limited to: oral administration, parenteral administration, inhalation administration, topical administration, rectal administration, nasal administration, oral administration, vaginal administration, administration by implant or other modes of administration. For example, parenteral administration used herein includes subcutaneous administration, intradermal administration, intravenous administration, intramuscular administration, intraarticular administration, intraarterial administration, intrasynovial cavity administration, intrasternal administration, intrathecal administration, intralesional administration and intracranial injection or infusion technology.

[0246] Generally, an effective amount of the compounds provided herein is administered. The amount of the compound actually administered can be determined by a physician according to the relevant circumstances, including the condition being treated, the route of administration selected, the compound actually administered, the age, weight and response of the individual patient, the severity of the patient's symptoms, and the like.

[0247] When used to prevent the conditions described herein, the compounds provided herein are administered to a subject at risk of developing the condition, typically based on the advice of a physician and under the supervision of a physician, at dosage levels as described above. Subjects at risk of developing a specific condition typically include those with a family history of the condition, or those identified by genetic testing or screening as being particularly susceptible to developing the condition.

[0248] The pharmaceutical compositions provided herein can also be administered over a long period of time ("chronic administration"). Chronic administration refers to administration of a compound or a pharmaceutical composition thereof over a long period of time, e.g., 3 months, 6 months, 1 year, 2 years, 3 years, 5 years, etc., or administration may continue indefinitely, e.g., for the rest of the subject's life. In some embodiments, chronic administration is intended to provide a constant level of the compound in the blood over a long period of time, e.g., within a therapeutic window.

[0249] Various methods of administration can be used to further deliver the pharmaceutical composition of the present invention. For example, in some embodiments, the pharmaceutical composition can be administered by push injection, for example, in order to increase the concentration of the compound in the blood to an effective level. The push dose depends on the target systemic level of the active component through the body, for example, the intramuscular or subcutaneous push dose slowly releases the active component, and the push delivered directly to the vein (for example, by IV intravenous drip) can be delivered more quickly, so that the concentration of the active component in the blood is quickly increased to an effective level. In other embodiments, the pharmaceutical composition can be given in a continuous infusion form, for example, by IV intravenous drip, so as to provide a steady-state concentration of the active component in the subject's body. In addition, in other embodiments, the pharmaceutical composition of the push dose can be first given, and then continuous infusion.

[0250] Oral compositions can be in the form of bulk liquid solutions or suspensions or bulk powders. However, more generally, in order to facilitate accurate dosing, the composition is provided in unit dosage form. The term "unit dosage form" refers to a physical discrete unit suitable as a unit dose for human patients and other mammals, each unit containing a predetermined amount of active substances suitable for producing the desired therapeutic effect and a suitable pharmaceutical excipient. Typical unit dosage forms include pre-filled, pre-measured ampoules or syringes of liquid compositions, or pills, tablets, capsules, etc. in the case of solid compositions. In such compositions, the compound is usually a relatively small component (about 0.1 to about 50% by weight, or preferably about 1 to about 40% by weight), and the remainder is various carriers or excipients and processing aids useful for forming the desired administration form.

[0251] For oral dosage, a representative regimen is one to five oral doses per day, especially two to four oral doses, typically three oral doses. Using these dosage modes, each dose provides about 0.01 to about 20 mg / kg of the compound of the invention, and preferred doses each provide about 0.1 to about 10 mg / kg, especially about 1 to about 5 mg / kg.

[0252] In order to provide blood levels similar to those using an injectable dose, or lower blood levels than using an injectable dose, a transdermal dose is generally selected in an amount of about 0.01 to about 20% by weight, preferably about 0.1 to about 20% by weight, preferably about 0.1 to about 10% by weight, and more preferably about 0.5 to about 15% by weight.

[0253] From about 1 to about 120 hours, especially 24 to 96 hours, the injected dosage level is in the range of about 0.1 mg / kg / hour to at least 10 mg / kg / hour. In order to obtain sufficient steady state levels, a preload bolus of about 0.1 mg / kg to about 10 mg / kg or more may also be given. For a 40 to 80 kg human patient, the maximum total dose cannot exceed about 2 g / day.

[0254] Liquid forms suitable for oral administration may include a suitable aqueous or non-aqueous carrier and buffers, suspending and dispersing agents, colorants, flavoring agents, etc. Solid forms may include, for example, any of the following components, or compounds of a similar nature: binders, such as microcrystalline cellulose, tragacanth, or gelatin; excipients, such as starch or lactose, disintegrants, such as alginic acid, Primogel, or corn starch; lubricants, such as magnesium stearate; glidants, such as colloidal silicon dioxide; sweeteners, such as sucrose or saccharin; or flavoring agents, such as peppermint, methyl salicylate, or orange flavoring.

[0255] Injectable compositions are typically based on injectable sterile saline or phosphate buffered saline, or other injectable excipients known in the art. As previously mentioned, in such compositions, the active compound is typically a minor component, often about 0.05 to 10% by weight, and the remainder is an injectable excipient, etc.

[0256] Typically, transdermal compositions are formulated as topical ointments or creams containing active ingredients. When formulated as an ointment, the active ingredient is typically combined with a paraffin or water-miscible ointment base. Alternatively, the active ingredient can be formulated as an ointment together with, for example, an oil-in-water cream base. Such transdermal formulations are well known in the art and typically include other components for enhancing the stable skin penetration of the active ingredient or formulation. All such known transdermal formulations and components are included within the scope provided by the invention.

[0257] The compounds of the invention may also be administered by transdermal means. Thus, transdermal administration may be achieved using patches of the reservoir or porous membrane type, or a variety of solid matrices.

[0258] The above components for oral administration, injection or topical administration are representative only. Other materials and processing techniques are described in Remington's Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pennsylvania, Part 8, which is incorporated herein by reference.

[0259] The compounds of the invention may also be administered in sustained release form or from a sustained release delivery system. Descriptions of representative sustained release materials can be found in Remington's Pharmaceutical Sciences.

[0260] The present invention also relates to pharmaceutically acceptable formulations of the compounds of the present invention. In one embodiment, the formulation comprises water. In another embodiment, the formulation comprises a cyclodextrin derivative. The most common cyclodextrins are α-, β- and γ-cyclodextrins consisting of 6, 7 and 8 α-1,4-linked glucose units, respectively, which optionally include one or more substituents on the linked sugar moiety, including but not limited to: methylated, hydroxyalkylated, acylated and sulfoalkyl ether substitutions. In some embodiments, the cyclodextrin is a sulfoalkyl ether β-cyclodextrin, for example, sulfobutyl ether β-cyclodextrin, also known as Captisol. See, for example, US5,376,645. In some embodiments, the formulation includes hexapropyl-β-cyclodextrin (e.g., in water, 10-50%).

[0261] Example

[0262] The reagents used in the present invention are commercial reagents purchased directly or synthesized by common methods well known in the art.

[0263] Notes on commonly used abbreviations:

[0264] PE = petroleum ether; EA = ethyl acetate; MeOH = methanol; DCM = dichloromethane; DCE = dichloroethane; CH3CN = acetonitrile; 1,4-dioxane = 1,4-dioxane; DMSO = dimethyl sulfoxide; HFIP = hexafluoroisopropanol; DMF = N,N-dimethylformamide; DME = ethylene glycol dimethyl ether; Hex = n-hexane; IPA = isopropanol; NMP = N-methylpyrrolidone; NMO = N-methylmorpholine-N-oxide; TEA = triethylamine; DIEA = diisopropylethylamine; CuI = cuprous iodide; CuC N = cuprous cyanide; triphosgene = triphosgene; p-TsOH = p-toluenesulfonic acid; T3P = 1-propylphosphoric acid cyclic anhydride; TsN3 = p-toluenesulfonyl azide; PPA = polyphosphoric acid; SEM-Cl = 2-(trimethylsilyl)ethoxymethyl chloride; DMC = diethyl carbonate; NBS = N-bromosuccinimide; TBS-Cl = tert-butyldimethylchlorosilane; LDA = lithium diisopropylamide; HMPA = hexamethylphosphoric triamide; HATU = 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate.

[0265] MSI-H = microsatellite instability-high; MSI-L = microsatellite instability-low; MSS = microsatellite stable.

[0266] Example 1: Preparation of key intermediates

[0267] Preparation of intermediate a1

[0268]

[0269] Steps: Dissolve the raw materials ethyl acetoacetate a1-1 (9.0 g, 69.2 mmol) and 5-bromo-1-H-3-amino 1,2,4-triazole a1-2 (11.3 g, 69.2 mmol) in 90 mL of ethanol, slowly add polyphosphoric acid PPA (8.0 g, 69.2 mmol), and heat to 80 ° C for 12 hours, cool to room temperature, and evaporate the solvent under reduced pressure. Pour the reaction solution into 100 mL of ice water, adjust the pH to about 8 with saturated sodium bicarbonate aqueous solution, extract with dichloromethane, dry with anhydrous sodium sulfate, and concentrate to obtain a white solid a1 (7.5 g), yield: 45%. LCMS ESI-MS m / z: 243 [M+H] + .

[0270] Preparation of intermediates a5, a7-a13

[0271]

[0272] Step 1: Dissolve the raw material a5-1 (24.0 g, 134 mmol) and tert-butyl piperazine-1-carboxylate (25.0 g, 134 mmol) in 240 mL of acetonitrile, slowly add TEA (40.8 g, 403 mmol), and heat to 60 ° C for 16 hours, cool to room temperature, and evaporate the solvent under reduced pressure. Pour the reaction solution into 100 mL of ice water, extract with dichloromethane, dry with anhydrous sodium sulfate, concentrate, and separate the crude product by column chromatography (PE / EA, 9 / 1) to obtain a yellow oil a5-2 (24 g), yield: 54%. LCMS ESI-MS m / z: 329 [M+H] + .

[0273] Step 2: Dissolve the intermediate a5-2 (22.2 g, 67.6 mmol) and 5-bromo-1-H-3-amino 1,2,4-triazole a1-2 (11.0 g, 67.6 mmol) in 200 mL of ethanol, slowly add polyphosphoric acid PPA (7.8 g, 67.6 mmol), and heat to 80 ° C for 12 hours, cool to room temperature, and evaporate the solvent under reduced pressure. Pour the reaction solution into 100 mL of ice water, adjust the pH to about 8 with saturated sodium bicarbonate aqueous solution, extract with dichloromethane, dry with anhydrous sodium sulfate, concentrate, and separate the crude product by column chromatography (PE / EA, 3 / 1) to obtain a yellow solid a5 (4.4 g), yield: 15%. LCMS ESI-MS m / z: 427 [M+H] + .

[0274] Referring to the synthetic route of intermediate a1 or a5, similar raw materials / analogues were used to synthesize the following target intermediates.

[0275]

[0276] Preparation of intermediates a2, a6, a14-a32

[0277]

[0278] Steps: Dissolve the intermediate a1 (7.5 g, 30.9 mmol) and the raw material a2-1 (10.1 g, 37.0 mmol) in 75 mL NMP, slowly add DIEA (12.0 g, 92.6 mmol), and heat to 50 ° C for 16 hours, cool to room temperature, and stop the reaction. Pour the reaction solution into 100 mL of ice water, extract with dichloromethane, dry with anhydrous sodium sulfate, concentrate, and separate the crude product by HPLC preparative chromatography (chromatographic column: XSelect Prep OBD C18 Column, 30*150 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: acetonitrile; flow rate: 90 mL / min; retention time: 3 min), and obtain a2 (5.2 g) as a yellow solid, yield: 35%). LCMS ESI-MS m / z: 478 [M+H] + .

[0279]

[0280] Steps: Dissolve the intermediate a5 (1.1 g, 2.57 mmol) and the raw material a2-1 (1.1 g, 3.86 mmol) in 11 mL NMP, slowly add DIEA (1.0 g, 7.72 mmol), add dropwise, heat to 70 ° C and react for 12 hours, cool to room temperature, and stop the reaction. Pour the reaction solution into 50 mL of ice water, extract with dichloromethane, dry with anhydrous sodium sulfate, concentrate, and separate the crude product by flash reverse column chromatography (chromatographic column: C18; CH3CN / H2O=5 / 1) to obtain a yellow solid a6 (996 mg), yield: 58%. LCMSESI-MS m / z: 662 [M+H] + .

[0281] Referring to the synthetic route of intermediate a2 or a6, similar raw materials / analogues were used to synthesize the following target intermediates.

[0282] [Using similar heteroaryl NH2 as raw material, reacting with chloroacetyl chloride to synthesize a2-1 analogues]

[0283]

[0284]

[0285] Preparation of intermediate a3

[0286]

[0287] Steps: Under nitrogen protection, the intermediate a2 (5.0 g, 10.4 mmol), the raw material a3-1 (2.9 g, 13.6 mmol) and sodium carbonate (3.3 g, 31.3 mmol) were dissolved in a mixed solution of 50 mL 1,4-dioxane and water (v / v, 4 / 1), and the catalyst Pd(dppf)Cl2 (900 mg, 1.0 mmol) was added. The mixed solution was heated to 100 ° C for 2 hours, the reaction was stopped, and filtered. 100 mL of water was added to the reaction solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by HPLC preparative chromatography (chromatographic column: WelFlash C18-I, 20-40 μm, 330 g; mobile phase A water: (10 mmol / L NH4HCO3), mobile phase B: acetonitrile; flow rate: 80 mL / min; retention time: 12 min) to obtain a yellow solid a3 (2.6 g), yield: 52%. LCMS ESI-MS m / z:482[M+H] + .

[0288] Preparation of intermediate a4

[0289]

[0290] Steps: Dissolve the intermediate a3 (2.4 g, 5.0 mmol) in 25 mL DMF, add NBS (1.8 g, 10.0 mmol), react the mixture at room temperature for 2 hours, stop the reaction, and filter. Add 100 mL of water to the reaction solution, extract with ethyl acetate, dry with anhydrous sodium sulfate, concentrate, and separate the crude product by HPLC preparative chromatography (chromatographic column: WelFlash C18-I, 20-40 μm, 330 g; mobile phase A water: (10 mmol / L NH4HCO3), mobile phase B: acetonitrile; flow rate: 90 mL / min; retention time: 11 min) to obtain a white solid a4 (1.6 g), yield: 57%. LCMS ESI-MS m / z: 560 [M+H] + .

[0291] Preparation of intermediate b1

[0292]

[0293] Step 1: Under nitrogen protection, the raw material 4,6-dichloro-5-methoxypyrimidine b1-1 (20.0 g, 111 mmol), the raw material methylboric acid (7.0 g, 117 mmol) and potassium phosphate (59.2 g, 279 mmol) were dissolved in 120 mL DME, and the catalyst Pd(dppf)Cl2 (4.6 g, 5.6 mmol) was added. The mixed solution was heated to 85°C and reacted for 12 hours, the reaction was stopped, and filtered. 100 mL of water was added to the reaction solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by column chromatography (PE / EA, 10 / 1) to obtain a white solid b1-2 (6.0 g), with a yield of 34%. LCMS ESI-MS m / z: 159 [M+H] + .

[0294] Step 2: Under a carbon monoxide atmosphere, the intermediate b1-2 (6.0 g, 37.0 mmol) and TEA (7.66 g, 75.0 mmol) were dissolved in 90 mL of methanol, and the catalyst Pd(dppf)Cl2 (1.85 g, 2.3 mmol) was added. The mixture was heated to 100°C under CO (20 atm) for 12 hours, the reaction was stopped, and the mixture was filtered. The solvent was evaporated under reduced pressure, and the crude product was separated by HPLC preparative chromatography (chromatographic column: WelFlash C18-I, 20-40 um, 120 g; mobile phase A: water (10 mmol / L NH4HCO3) mobile phase B: acetonitrile; flow rate: 60 mL / min) to obtain a white solid b1-3 (5.0 g), with a yield of 73%. LCMS ESI-MS m / z: 183 [M+H] + .

[0295] Step 3: Dissolve the intermediate b1-3 (3.0 g, 16.5 mmol) in 15 mL of HBr aqueous solution (40%), heat to 40 ° C and react for 10 hours, then stop the reaction. Add HI (15 mL) to the reaction solution, continue to react at 40 ° C for 6 hours, and evaporate the solvent under reduced pressure. Adjust the pH of the crude product to about 8 with NaOH aqueous solution (1N), then adjust the pH to about 3 with concentrated hydrochloric acid, and evaporate the solvent under reduced pressure. The crude product was separated by flash reverse column chromatography (chromatographic column: C18; CH3CN / H2O, 1 / 1) to obtain a yellow solid b1 (1.5 g), yield: 59%. LCMS ESI-MS m / z: 155 [M+H] + .

[0296] Preparation of intermediate b2

[0297]

[0298] Step 1: In an ice bath, under nitrogen protection, the raw material b2-1 (500 mg, 3.81 mmol) was dissolved in 10 mL of tetrahydrofuran, and NBS (679 mg, 3.81 mmol) was added. The mixed solution was reacted at room temperature for 0.5 hours, the reaction was stopped, and filtered. Saturated sodium bicarbonate aqueous solution was added to the reaction solution to adjust the pH to about 8, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by column chromatography (PE / EA, 10 / 1) to obtain a yellow oil b2-2 (540 mg), with a yield of 63%. LCMS ESI-MS m / z: 224 [M+H] + .

[0299] Step 2: Under nitrogen protection, the intermediate b2-2 (510 mg, 2.28 mmol) of the previous step was dissolved in 3 mL of diethyl carbonate DMC, CH3ONa (185 mg, 3.42 mmol) was added, and the mixture was heated to 125°C for 0.5 hours and cooled to room temperature. 20 mL of ice water was added to the reaction solution, extracted with methyl tert-butyl ether, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by column chromatography (PE / EA, 1 / 1) to obtain a yellow oil b2-3 (300 mg), with a yield of 64%. LCMS ESI-MS m / z: 205 [M+H] + .

[0300] Step 3: Under nitrogen protection at -78°C, the intermediate b2-3 (300 mg, 1.46 mmol) from the previous step was dissolved in 6 mL of anhydrous tetrahydrofuran and added dropwise n BuLi (2.5M, 1.47mL) was added, and stirring was continued for 1 hour. Isopropyl alcohol pinacol borate (327mg, 1.75mmol) was added to the reaction solution, and the reaction was continued at -78°C for 1 hour. The mixture was quenched with saturated aqueous ammonium chloride solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated to obtain a yellow oil b2 (300mg), with a yield of 81%. LCMSESI-MS m / z: 253[M+H] + .

[0301] Preparation of intermediate b3

[0302]

[0303] Step 1: Under carbon monoxide atmosphere (30 atm), the raw material 4-chloro-5-methoxypyrimidine b3-1 (5.0 g, 34.6 mmol) and TEA (7.0 g, 69.2 mmol) were dissolved in 100 mL of methanol, and the catalyst Pd(dppf)Cl2 (1.5 g, 2.07 mmol) was added. The mixture was heated to 100°C under the protection of carbon monoxide for 12 hours, the reaction was stopped, and the mixture was filtered. The solvent was evaporated under reduced pressure, and the crude product was separated by column chromatography (PE / EA, 1 / 1) to obtain a yellow oil b3-2 (4.0 g), with a yield of 69%. LCMS ESI-MS m / z: 275 [M+H] + .

[0304] Step 2: Dissolve the intermediate b3-2 (1.0 g, 5.94 mmol) in 20 mL of aqueous solution, add NaOH (0.5 g, 11.9 mmol), heat to 40 °C and react for 10 hours to stop the reaction. Add dilute hydrochloric acid to the reaction solution to adjust the pH to about 5, and evaporate the solvent under reduced pressure. The crude product was separated by flash reverse column chromatography (chromatographic column: C18; CH3CN / H2O, 1 / 10) to obtain a white solid b3 (400 mg), yield: 44%. LCMS ESI-MS m / z: 155 [M+H] + .

[0305] Preparation of intermediate b4

[0306]

[0307] Step 1: In an ice bath, under nitrogen protection, the raw material 4,6-dichloro-5-methoxypyrimidine b1-1 (11.0 g, 61.5 mmol) was dissolved in 220 mL of anhydrous tetrahydrofuran, and a solution of CD3MgI (1M, 62 mL) in ether was added dropwise. After the addition, the mixture was reacted at room temperature for 12 hours and the reaction was stopped. 100 mL of water was added to the reaction solution, the organic solvent was evaporated under reduced pressure, the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by column chromatography (PE / EA, 1 / 1) to obtain a yellow oil b4-1 (4.0 g), with a yield of 40%. LCMS ESI-MS m / z: 161 [M+H] + .

[0308] Step 2: Under a carbon monoxide atmosphere, the intermediate b4-1 (5.0 g, 30.9 mmol) and TEA (9.3 g, 92.8 mmol) from the previous step were dissolved in 50 mL of deuterated methanol CD3OD, and the catalyst Pd(dppf)Cl2 (0.7 g, 0.93 mmol) was added. The mixed solution was heated to 100°C under CO (30 atm) for 12 hours, the reaction was stopped, and the mixture was filtered. 300 mL of water was added to the reaction solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by column chromatography (PE / EA, 1 / 1) to obtain a yellow oil b4-2 (2.0 g), with a yield of 35%. LCMS ESI-MS m / z: 186 [M+H] + .

[0309] Step 3: Dissolve the intermediate b4-2 (1.0 g, 5.4 mmol) in 20 mL of heavy water D2O, add NAOH (0.4 g, 10.8 mmol) to the reaction solution, react at room temperature for 6 hours, and evaporate the solvent under reduced pressure. Adjust the pH of the crude product to about 5 with dilute hydrochloric acid (2 M), and evaporate the solvent under reduced pressure. The crude product was separated by flash reverse column chromatography (chromatographic column: C18; CH3CN / H2O, 1 / 20) to obtain a white solid b4 (920 mg), yield: 99%. LCMS ESI-MS m / z: 172 [M+H] + .

[0310] Preparation of intermediates c1-c4

[0311]

[0312] Step 1: Under nitrogen protection, the intermediate a4 (210 mg, 0.3 mmol) and TEA (114 mg, 1.1 mmol) were dissolved in 2 mL DMSO, and the raw material c1-1 (371 mg, 1.9 mmol) was added. The mixture was heated to 85 ° C for 12 hours to stop the reaction. 100 mL of water was added to the reaction solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by HPLC chromatography (chromatographic column: WelFlash C18-I, 20-40 μm, 180 g; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: acetonitrile; flow rate: 70 mL / min; retention time: 12 min) to obtain a white solid c1-2 (120 mg), yield: 47%. LCMS ESI-MS m / z: 678 [M+H] + .

[0313] Step 2: Dissolve the intermediate c1-1 (120 mg, 0.2 mmol) and trifluoroacetic acid (0.5 mL) in 2 mL of dichloromethane, react at room temperature for 2 hours, and stop the reaction. Evaporate the solvent under reduced pressure, and separate the crude product by HPLC preparative chromatography (chromatographic column: WelFlash C18-I, 20-40 um, 40 g; mobile phase A: water (10 mmol / L NH4HCO3) mobile phase B: acetonitrile; flow rate: 50 mL / min; retention time: 9 min) to obtain white solid c1 (80 mg), yield: 78%. LCMS ESI-MS m / z: 578 [M+H] + .

[0314] Referring to the synthetic route of intermediate c1, similar raw materials / analogues were used to synthesize the following target intermediate.

[0315]

[0316] Preparation of intermediates C5-C6, C12-C17

[0317]

[0318] Step 1: Dissolve the intermediate a6 (996 mg, 1.5 mmol) in 10 mL of dichloromethane, add 0.5 mL of trifluoroacetic acid, and react the mixture at room temperature for 1 hour to stop the reaction. Add 20 mL of water to the reaction solution, adjust the pH to about 9 with a saturated sodium bicarbonate aqueous solution, extract with dichloromethane, dry with anhydrous sodium sulfate, and concentrate to obtain a yellow solid c5-2 (694 mg), yield: 82%. LCMS ESI-MS m / z: 562 [M+H] + .

[0319] Step 2: Dissolve the intermediate c5-2 (494 mg, 0.88 mmol) and DIEA (567 mg, 4.4 mmol) in 5 mL of dichloromethane, add the raw material 3-hydroxy-2-pyridinecarbonyl chloride c5-1 (277 mg, 1.76 mmol), react at room temperature for 2 hours, and stop the reaction. The solvent was evaporated under reduced pressure, and the crude product was separated by flash column chromatography (chromatographic column: WelFlash C18-I, 20-40um, 130g; mobile phase A: water, mobile phase B: acetonitrile; flow rate: 60 mL / min; retention time: 14 min) to obtain a yellow solid c5 (360 mg), yield: 60%. LCMS ESI-MS m / z: 683 [M+H] + .

[0320]

[0321] Steps: In an ice bath, under nitrogen protection, the intermediate b1 (49 mg, 0.32 mmol) and 1-chloro-N, N, 2-trimethylpropyl-1-enyl-1-amine (43 mg, 0.32 mmol) were dissolved in 2 mL of dichloromethane and stirred for 1 hour in an ice bath. DIEA (138 mg, 1.06 mmol) and intermediate c5-2 (120 mg, 0.21 mmol) were added to the reaction solution, reacted at room temperature for 1 hour, and the reaction was stopped. 15 mL of water was added to the reaction solution, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by flash reverse column chromatography (chromatographic column: C18; CH3CN / H2O, 4 / 5) to obtain a light yellow solid c6 (45 mg), yield: 30%. LCMS ESI-MS m / z: 698 [M+H] + .

[0322] Referring to the synthetic route of intermediate C5 or C6, similar raw materials / analogues were used to synthesize the following target intermediates.

[0323]

[0324]

[0325] Preparation of intermediates C7-C11

[0326]

[0327] Step 1: Under nitrogen protection, the intermediate a5 (2.5 g, 5.85 mmol), the raw material a3-1 (1.2 g, 5.85 mmol) and sodium carbonate (1.9 g, 17.5 mmol) were dissolved in 50 mL of a mixed solution of 1,4-dioxane and water (v / v, 1 / 1), and the catalyst Pd(dppf)Cl2 (400 mg, 0.59 mmol) was added. The mixture was heated to 100 °C for 12 hours, the reaction was stopped, and the mixture was filtered. 100 mL of water was added to the reaction solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by HPLC preparative chromatography (chromatographic column: WelFlash C18-I, 20-40 μm, 330 g; mobile phase A water: (10 mmol / L NH4HCO3), mobile phase B: acetonitrile; flow rate: 40 mL / min; retention time: 16 min) to obtain a yellow oil c7-1 (1.5 g), yield: 58%. LCMS ESI-MS m / z: 431 [M+H] + .

[0328] Step 2: Dissolve the intermediate c7-1 (1.5 g, 3.48 mmol) and the raw material ethyl bromoacetate c7-2 (0.8 g, 4.88 mmol) in 25 mL 1,4-dioxane, slowly add DIEA (1.4 g, 10.5 mmol), and heat to 80 ° C for 4 hours, cool to room temperature, and stop the reaction. Pour the reaction solution into 100 mL ice water, extract with dichloromethane, dry with anhydrous sodium sulfate, concentrate, and separate the crude product by HPLC preparative chromatography (chromatographic column: XSelect Prep OBD C18 Column, 30*150 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: acetonitrile; flow rate: 40 mL / min; retention time: 16 min) to obtain yellow solid c7-3 (1.4 g), yield: 78%. LCMS ESI-MS m / z: 517 [M+H] + .

[0329] Step 3: Dissolve the intermediate c7-3 (1.2 g, 2.32 mmol) in a mixed solution of 18 mL tetrahydrofuran and water (v / v, 2 / 1), slowly add NAOH aqueous solution (3.5 mL, 1 M), dropwise, react at room temperature for 1 hour, and stop the reaction. Adjust the pH of the reaction solution to about 4 with dilute hydrochloric acid, extract with dichloromethane, dry with anhydrous sodium sulfate, concentrate, and separate the crude product by HPLC preparative chromatography (chromatographic column: XSelect Prep OBD C18 Column, 30*150 mm, 5 μm; mobile phase A: water, mobile phase B: acetonitrile; flow rate: 40 mL / min; retention time: 16 min) to obtain yellow solid c7 (900 mg), yield: 92%. LCMS ESI-MS m / z: 489 [M+H] + .

[0330] Referring to the synthetic route of intermediate c7, similar raw materials / analogues were used to synthesize the following target intermediate.

[0331]

[0332] Preparation of intermediate C18

[0333]

[0334] Step 1: Under nitrogen protection, the intermediate a1 (1.42 g, 5.85 mmol), the raw material b2 (1.47 g, 5.85 mmol) and sodium carbonate (1.9 g, 17.5 mmol) were dissolved in a mixed solution of 30 mL 1,4-dioxane and water (v / v, 1 / 1), and the catalyst Pd(dppf)Cl2 (400 mg, 0.59 mmol) was added. The mixed solution was heated to 100 ° C for 2 hours, the reaction was stopped, and filtered. 80 mL of water was added to the reaction solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by column chromatography (PE / EA, 1 / 1) to obtain a yellow solid c18-1 (1.0 g), with a yield of 60%. LCMS ESI-MS m / z: 289 [M+H] + .

[0335] Step 2: Dissolve the intermediate c18-1 (1.0 g, 3.47 mmol) and the raw material ethyl bromoacetate c7-2 (0.8 g, 4.88 mmol) in 25 mL 1,4-dioxane, slowly add DIEA (1.4 g, 10.5 mmol), add dropwise, heat to 80 ° C for 4 hours, cool to room temperature, and stop the reaction. Pour the reaction solution into 100 mL ice water, extract with dichloromethane, dry with anhydrous sodium sulfate, concentrate, and separate the crude product by flash reverse column chromatography (chromatographic column: C18; CH3CN / H2O, 3 / 1) to obtain a light yellow solid c18-2 (1.1 g), yield: 85%. LCMS ESI-MS m / z: 375 [M+H] + .

[0336] Step 3: Dissolve the intermediate c18-2 (1.1 g, 2.94 mmol) in a mixed solution of 30 mL tetrahydrofuran and water (v / v, 2 / 1), slowly add NAOH aqueous solution (5.0 mL, 1 M), dropwise, react at room temperature for 1 hour, and stop the reaction. Adjust the pH of the reaction solution to about 4 with dilute hydrochloric acid, extract with dichloromethane, dry with anhydrous sodium sulfate, concentrate, and separate the crude product by HPLC preparative chromatography (chromatographic column: XSelect Prep OBD C18 Column, 30*150 mm, 5 μm; mobile phase A: water, mobile phase B: acetonitrile; flow rate: 60 mL / min) to obtain yellow solid c18 (730 mg), yield: 72%. LCMS ESI-MS m / z: 347 [M+H] + .

[0337] Preparation of intermediates d1-d7

[0338]

[0339] Step 1: Under nitrogen protection, the raw material d1-1 (2.0 g, 7.40 mmol) and methylhydrazine sulfate (1.1 g, 7.40 mmol) were dissolved in 40 mL of ethanol, acetic acid (100 mg, 0.14 mmol) was added, and the mixture was heated to 80 ° C for 2 hours, the reaction was stopped, and the solvent was evaporated under reduced pressure. Saturated sodium bicarbonate aqueous solution was added to the mixture to adjust the pH to about 8, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated to obtain a yellow oil d1-2 (2.5 g), yield: 89%. LCMS ESI-MS m / z: 297 [M+H] + .

[0340] Step 2: Under nitrogen protection, the intermediate d1-2 (2.5 g, 8.38 mmol) and potassium phosphate (1.78 g, 8.39 mmol) were dissolved in 38 mL DMSO, and the catalyst CuI (160 mg, 0.83 mmol) was added. The mixture was heated to 100 ° C for 3 hours, the reaction was stopped, and filtered. 100 mL of water was added to the reaction solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by HPLC preparative chromatography (chromatographic column: WelFlash C18-I, 20-40 μm, 330 g; mobile phase A water: (0.1% TFA), mobile phase B: acetonitrile; flow rate: 40 mL / min; retention time: 12 min) to obtain a white solid d1-3 (130 mg), yield: 7%. LCMS ESI-MS m / z: 217 [M+H] + .

[0341] Step 3: -78°C, under nitrogen protection, the intermediate d1-3 (130 mg, 0.59 mmol) of the previous step was dissolved in 2.5 mL of anhydrous tetrahydrofuran, and n-BuLi (0.28 mL, 2.5 M) was slowly added. After the addition was complete, the mixture was stirred at -78°C for 1 hour. 2-isopropoxyboronic acid pinacol ester (134 mg, 1.23 mmol) was added to the reaction solution, and stirring was continued for 30 minutes to stop the reaction. 10 mL of saturated aqueous ammonium chloride solution and ethyl acetate were added to the reaction solution, dried over anhydrous sodium sulfate, and concentrated to obtain a yellow oil d1 (110 mg), with a yield of 70%. LCMS ESI-MS m / z: 265 [M+H] + .

[0342] Referring to the synthetic route of intermediate d1, similar raw materials / analogues were used to synthesize the following target intermediate.

[0343]

[0344]

[0345] Preparation of intermediates d8 and d15

[0346]

[0347] Step 1: Under nitrogen protection, the raw material 1-bromo-2-fluoro-4-iodobenzene d8-1 (1.95 g, 6.5 mmol) and the raw material d8-2 (2.32 g, 7.8 mmol) were dissolved in 40 mL of acetonitrile, potassium tert-butoxide (2.2 g, 19.4 mmol) was added, and the mixture was heated to 50°C for 6 hours, the reaction was stopped, and filtered. 100 mL of water was added to the reaction solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by column chromatography (PE / EA, 20 / 1) to obtain a yellow oil d8-3 (2.22 g), with a yield of 79%.

[0348] Step 2: Dissolve the intermediate d8-3 (2.22 g, 5.15 mmol) in 133 mL of chlorobenzene, add polyphosphoric acid PPA (2.37 g, 20.6 mmol), heat the mixture to 130 ° C and react for 5 hours, stop the reaction, and cool to room temperature. Add 100 mL of ice water to the reaction solution, extract with ethyl acetate, dry with anhydrous sodium sulfate, concentrate, and separate the crude product by flash reverse column chromatography (chromatographic column: C18; CH3CN / H2O, 9 / 10) to obtain a yellow oil d8-4 (1.05 g), yield: 60%.

[0349] Step 3: Under nitrogen protection, the intermediate d8-4 (1.05 g, 3.1 mmol) and the raw material d8-5 (1.95 g, 9.3 mmol) of the previous step were dissolved in 21 mL DMF, and the catalyst CuI (290 mg, 1.55 mmol) and HMPA (2.39 g, 13.3 mmol) were added. The mixture was heated to 100 ° C for 2 hours, the reaction was stopped, and the mixture was filtered. 60 mL of water was added to the reaction solution, extracted with methyl tert-butyl ether, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by column chromatography (PE / EA, 100 / 1) to obtain a yellow solid d8-6 (0.8 g), with a yield of 92%.

[0350] Step 4: Under nitrogen protection, the intermediate d8-6 (0.8 g, 2.85 mmol) and the raw material diphenyl ketone imine (1.03 g, 5.69 mmol) were dissolved in 16 mL of toluene, and the catalyst Pd(OAc)2 (60 mg, 0.28 mmol), the ligand BINAP (0.35 g, 0.57 mmol) and cesium carbonate (1.85 g, 5.69 mmol) were added. The mixture was heated to 110 ° C for 2 hours, the reaction was stopped, and filtered. 60 mL of water was added to the reaction solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated to obtain a crude mixture. The mixture was dissolved in 4 mL of tetrahydrofuran, and a 2M concentration of hydrogen chloride in tetrahydrofuran solution (16 mL) was added. The reaction was carried out at room temperature for 1 hour and the reaction was stopped. Saturated sodium bicarbonate aqueous solution was added to the reaction solution to adjust the pH to about 8, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by flash reverse column chromatography (chromatographic column: C18; CH3CN / H2O, 10 / 7) to obtain a yellow solid d8 (0.5 g), yield: 81%. LCMS ESI-MS m / z: 218 [M+H] + .

[0351] Referring to the synthetic route of intermediate d8, similar raw materials / analogues were used to synthesize the following target intermediate.

[0352]

[0353] Preparation of intermediate d9

[0354]

[0355] Step 1: Under nitrogen protection, raw material d9-1 (3.5 g, 27.3 mmol) and raw material d9-2 (4.1 g, 32.8 mmol) were dissolved in 70 mL of dichloromethane, DIEA (10.6 g, 81.9 mmol) was added, and the mixture was reacted at room temperature for 3 hours to stop the reaction. 100 mL of water was added to the reaction solution, extracted with dichloromethane, dried over anhydrous sodium sulfate, and concentrated to obtain a yellow oil d9-3 (3.3 g).

[0356] Step 2: Dissolve the intermediate d9-3 (1.7 g, 7.86 mmol) in 17 mL of acetonitrile, add InCl3 (0.35 g, 1.57 mmol), heat the mixture to 80 °C and react for 5 hours, stop the reaction, and cool to room temperature. Add 100 mL of ice water to the reaction solution, extract with ethyl acetate, dry over anhydrous sodium sulfate, and concentrate to obtain a yellow oil d9-4 (1.5 g).

[0357] 1H NMR (400MHz, DMSO-d6) δ7.35(d,J=4.9Hz,1H),6.87(d,J=5.0Hz,1H),4.73(s,2H),3.84(t,J=5.6Hz,2H),2.66(d,J=11.3Hz,2H).

[0358] Step 3: Under nitrogen protection, the intermediate d9-4 (1.5 g, 7.56 mmol) of the previous step was dissolved in 30 mL of toluene, and NBS (1.3 g, 7.56 mmol) was added. The mixture was reacted at room temperature for 12 hours, the reaction was stopped, and filtered. 60 mL of water was added to the reaction solution, extracted with methyl tert-butyl ether, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by column chromatography (PE / EA, 100 / 1) to obtain a yellow oil d9-5 (500 mg), with a yield of 17%.

[0359] 1 H NMR (300MHz, DMSO-d6) δ6.99(s,1H),4.62(s,2H),3.83(t,J=5.6Hz,2H),2.61(tt,J=5.7,1.9Hz,2H).

[0360] Step 4: -78°C, under nitrogen protection, the intermediate d9-5 (0.5 g, 2.28 mmol) of the previous step was dissolved in 10 mL of anhydrous tetrahydrofuran, and a hexane solution of n-BuLi (1.4 mL, 2M) was added dropwise. After the addition was completed, the mixture was stirred for 30 minutes. Isopropoxyboronic acid pinacol ester iPrOBpin (0.51 g, 2.74 mmol) was added to the mixture, and the mixture was reacted at room temperature for 1 hour to stop the reaction. 60 mL of saturated NH4Cl aqueous solution was added to the reaction solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated to obtain a yellow solid d9 (550 mg), with a yield of 91%. LCMS ESI-MS m / z: 267 [M+H] + .

[0361] Preparation of intermediates d10-d11

[0362]

[0363] Steps: Under nitrogen protection, the raw material d10-1 (50 mg, 0.23 mmol) and the diboric acid pinacol ester B2Pin2 (89 mg, 0.35 mmol) were dissolved in 1 mL of 1,4-dioxane, and the catalyst Pd(dppf)Cl2 (17 mg, 0.02 mmol) and KOAc (57 mg, 0.58 mmol) were added. The mixture was heated to 80°C for 2 hours, the reaction was stopped, and filtered. 5 mL of water was added to the reaction solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated to obtain a yellow solid d10 (20 mg), with a yield of 33%. LCMSESI-MS m / z: 263 [M+H] + .

[0364] Referring to the synthetic route of intermediate d10, similar raw materials / analogues were used to synthesize the following target intermediate.

[0365]

[0366] Preparation of intermediate d12

[0367]

[0368] Step 1: Under nitrogen protection, the raw material d12-1 (2.5 g, 12.88 mmol) and imidazole (1.8 g, 25.77 mmol) were dissolved in 40 mL of dichloromethane, TBS-Cl (2.1 g, 14.2 mmol) was added, and the mixture was reacted at room temperature for 1 hour to stop the reaction. 100 mL of water was added to the reaction solution, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by column chromatography (PE / EA, 10 / 1) to obtain a yellow oil d12-2 (3.0 g), with a yield of 76%. LCMS ESI-MS m / z: 308 [M+H] + .

[0369] Step 2: -78℃, under nitrogen protection, dissolve the intermediate d12-2 (1.0g, 3.24mmol) in 23mL of anhydrous tetrahydrofuran, add n-BuLi (1.3mL, 2.5M) in hexane dropwise, and stir the mixture for 30 minutes. Add the pre-prepared tetrahydrofuran solution of ZnCl2 (10.7mL, 1M) to the reaction solution, continue the reaction for 1 hour, and stop the reaction. Use it directly in the next step.

[0370] Preparation of intermediate d13

[0371]

[0372] Step 1: -78°C, under nitrogen protection, dissolve the raw material d13-1 (1.1 g, 4.24 mmol) in 10 mL of anhydrous tetrahydrofuran, add LDA (4.24 mL, 2M) in hexane dropwise, add the pre-prepared I2 (1.62 g, 6.36 mmol, 1 mL) tetrahydrofuran solution, react the mixture at -78°C for 1 hour, and stop the reaction. Add 50 mL of saturated sodium thiosulfate Na2S2O3 aqueous solution to the reaction solution, extract with dichloromethane, dry with anhydrous sodium sulfate, concentrate, and separate the crude product by flash reverse column chromatography (chromatographic column: C18; CH3CN / H2O, 7 / 10) to obtain a yellow solid d13-2 (310 mg), yield: 18%. LCMS ESI-MSm / z: 386[M+H] + .

[0373] Step 2: Dissolve the intermediate d13-2 (386 mg, 1.0 mmol) in 4 mL of methanol, add NaOH (3.9 mL, 2.5 N) aqueous solution, and react the mixture at room temperature for 1 hour. Add 30 mL of ice water to the reaction solution, extract with ethyl acetate, dry with anhydrous sodium sulfate, and concentrate to obtain a yellow solid d13-3 (200 mg), yield: 81%. LCMS ESI-MS m / z: 246 [M+H] + .

[0374] Step 3: In an ice bath, dissolve the intermediate d13-3 (0.2 g, 0.81 mmol) in 4 mL DMF, slowly add NaH (30 mg, 1.22 mmol, 60%), stir for 1 hour, add SEM-Cl (0.2 g, 1.22 mmol) to the reaction solution, warm the mixture to room temperature and react for 1 hour to stop the reaction. Add 50 mL of ice water to the reaction solution, extract with dichloromethane, dry with anhydrous sodium sulfate, concentrate, and separate the crude product by flash reverse column chromatography (chromatographic column: C18; CH3CN / H2O, 1 / 1) to obtain a yellow solid d13-4 (200 mg), yield: 65%. LCMS ESI-MS m / z: 376 [M+H] + .

[0375] Step 4: -78°C, under nitrogen protection, the intermediate d13-4 (170 mg, 0.45 mmol) of the previous step was dissolved in 4 mL of anhydrous tetrahydrofuran, and a hexane solution of n-BuLi (0.22 mL, 2.5 M) was added dropwise. After the addition was completed, the mixture was stirred for 30 minutes. Isopropoxyboronic acid pinacol ester iPrOBpin (101 mg, 0.54 mmol) was added to the mixture, and the mixture was reacted at room temperature for 1 hour to stop the reaction. 60 mL of saturated NH4Cl aqueous solution was added to the reaction solution, extracted with dichloromethane, dried over anhydrous sodium sulfate, and concentrated to obtain a yellow solid d13 (80 mg), with a yield of 48%. LCMS ESI-MS m / z: 376 [M+H] + .

[0376] Preparation of intermediate d14

[0377]

[0378] Step 1: Dissolve the raw material d14-1 (2.4 g, 9.1 mmol) and TEA (2.75 g, 27.2 mmol) in 24 mL of anhydrous dichloromethane, add p-toluenesulfonyl chloride TsCl (3.1 g, 54.3 mmol) dropwise, react at room temperature for 12 hours, and stop the reaction. Add 50 mL of ice water to the reaction solution, extract with dichloromethane, dry with anhydrous sodium sulfate, concentrate, and separate the crude product by flash column chromatography (PE / EA, 3 / 1) to obtain a light pink solid d14-2 (3.1 g), yield: 81%. LCMS ESI-MS m / z: 420 [M+H] + .

[0379] Step 2: In an ice bath, under nitrogen protection, the intermediate d14-2 (3.1 g, 7.39 mmol) from the previous step was dissolved in 31 mL of ethanol, and NaBH4 (0.28 g, 7.39 mmol) was added. The mixture was reacted at room temperature for 1 hour. 30 mL of ice water was added to the reaction solution, and the pH was adjusted to about 6 with trifluoroacetic acid. The mixture was extracted with dichloromethane, dried over anhydrous sodium sulfate, and concentrated to obtain a yellow solid d14-3 (1.3 g). The yield was 41%. LCMS ESI-MS m / z: 422 [M+H] + .

[0380] Step 3: Dissolve the intermediate d14-3 (1.3 g, 3.09 mmol) in 12 mL of anhydrous tetrahydrofuran, slowly add NaH (123 mg, 3.09 mmol, 60%), and react the mixture at room temperature for 12 hours to stop the reaction. Add 40 mL of ice water to the reaction solution, extract with dichloromethane, dry with anhydrous sodium sulfate, concentrate, and separate the crude product by flash column chromatography (PE / EA, 50 / 1) to obtain a yellow solid d14-4 (440 mg), yield: 57%. LCMS ESI-MS m / z: 250 [M+H] + .

[0381] Step 4: -78°C, under nitrogen protection, the intermediate d14-4 (170 mg, 0.68 mmol) of the previous step was dissolved in 2 mL of anhydrous tetrahydrofuran, and a hexane solution of n-BuLi (0.27 mL, 2.5 M) was added dropwise. After the addition was completed, the mixture was stirred for 30 minutes. Isopropoxyboronic acid pinacol ester iPrOBpin (152 mg, 0.82 mmol) was added to the mixture, and the mixture was reacted at room temperature for 1 hour to stop the reaction. 10 mL of saturated NH4Cl aqueous solution was added to the reaction solution, extracted with dichloromethane, dried over anhydrous sodium sulfate, and concentrated to obtain a yellow solid d14 (120 mg), with a yield of 71%. LCMS ESI-MS m / z: 376 [M+H] + .

[0382] Preparation of intermediates d16-d17

[0383]

[0384] Steps: Under nitrogen protection, TMSCF3 (490 mg, 3.44 mmol) and KF (200 mg, 3.44 mmol) were dissolved in a mixed solution of 12 mL DMF and NMP (v / v, 1 / 1), and the catalyst CuI (657 mg, 3.44 mmol) was added and stirred at room temperature for 3 hours. Raw material d16-1 (600 mg, 2.29 mmol) was added to the reaction solution, and the mixture was heated to 70 ° C for 12 hours, the reaction was stopped, and filtered. 60 mL of water was added to the reaction solution, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by flash reverse column chromatography (chromatographic column: C18; CH3CN / H2O, 1 / 1) to obtain a brown oil d16 (150 mg), yield: 32%. LCMSESI-MS m / z: 204 [M+H] + .

[0385] Referring to the synthetic route of intermediate d16, similar raw materials / analogues were used to synthesize the following target intermediate.

[0386]

[0387] Preparation of intermediates d18-d19

[0388]

[0389] Step 1: Under nitrogen protection, the raw material 2-bromo-5-trifluoromethylphenol d18-1 (5.0 g, 20.75 mmol) and potassium carbonate (8.6 g, 62.2 mmol) were dissolved in 100 mL DMF, and the raw material d18-2 (12.3 g, 62.2 mmol) was added dropwise, and the mixture was heated to 80°C for 12 hours, the reaction was stopped, and filtered. 250 mL of water was added to the reaction solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by column chromatography (PE / EA, 20 / 1) to obtain a yellow oil d18-3 (6.0 g), with a yield of 81%.

[0390] Step 2: Dissolve the intermediate d18-3 (6.0 g, 16.8 mmol) and polyphosphoric acid (30 g, 261 mmol) in 72 mL of toluene, heat the mixture to 120 °C and react for 5 hours to stop the reaction. Add 100 mL of water to the reaction solution, adjust the pH to about 8 with ammonia water, extract with methyl tert-butyl ether, dry with anhydrous sodium sulfate, concentrate, and separate by column chromatography (PE / EA, 20 / 1) to obtain a yellow oil d18-4 (1.0 g), with a yield of 23%.

[0391] Step 3: Under nitrogen protection, the intermediate d18-4 (1.0 g, 3.77 mmol) and the raw material diphenyl ketone imine (1.4 g, 7.55 mmol) were dissolved in 20 mL of toluene, and the catalyst Pd(OAc)2 (80 mg, 0.38 mmol), the ligand BINAP (0.5 g, 0.8 mmol) and cesium carbonate (2.5 g, 7.55 mmol) were added. The mixture was heated to 110 ° C and reacted for 2 hours, the reaction was stopped, and filtered. 100 mL of water was added to the reaction solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated to obtain a crude mixture. The mixture was dissolved in 5 mL of tetrahydrofuran, and a 2M concentration of hydrogen chloride in tetrahydrofuran solution (20 mL) was added, and the reaction was stopped at room temperature for 1 hour. Saturated sodium bicarbonate aqueous solution was added to the reaction solution to adjust the pH to about 8, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by flash reverse column chromatography (chromatographic column: C18; CH3CN / H2O, 1 / 1) to obtain a yellow solid d18 (150 mg), yield: 20%. LCMS ESI-MS m / z: 202 [M+H] + .

[0392] Referring to the synthetic route of intermediate d18, similar raw materials / analogues were used to synthesize the following target intermediate.

[0393]

[0394] Preparation of intermediate d20

[0395]

[0396] Steps: -78°C, under nitrogen protection, the raw material 7-aminobenzofuran d20-1 (600 mg, 4.13 mmol) was dissolved in 14 mL of anhydrous dichloromethane, and the pre-prepared liquid Br2 solution (0.7 g, 4.13 mmol, DCM 11 mL) was added. The mixed solution was reacted at -78°C for 1 hour, and the reaction was stopped. 20 mL of saturated sodium thiosulfate aqueous solution was added to the reaction solution, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by flash reverse column chromatography (chromatographic column: C18; CH3CN / H2O, 1 / 1) to obtain a yellow oil d20 (200 mg), yield: 23%. LCMS ESI-MS m / z: 212 [M+H] + .

[0397] Preparation of intermediate d21

[0398]

[0399] Steps: Under nitrogen protection, 2-chloro-4-bromoaniline P23-1 (1.1 g, 5.32 mmol) and raw material pyridine-3-boric acid d21-1 (1.0 g, 7.99 mmol) were dissolved in a mixed solution of 20 mL DMF and water (v / v, 4 / 1), and catalyst Pd(dppf)Cl2 (400 mg, 0.53 mmol) and potassium carbonate (1.5 g, 10.65 mmol) were added. The mixture was heated to 110°C for 1 hour, the reaction was stopped, and filtered. 50 mL of water was added to the reaction solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated to obtain a crude mixture. The crude product was separated by flash reverse column chromatography (chromatographic column: C18;

[0400] CH3CN / H2O, 1 / 1) to give a yellow solid d21 (900 mg), yield: 83%. LCMS ESI-MS m / z: 205 [M+H] + .

[0401] Preparation of intermediate d22

[0402]

[0403] Step 1: In an ice bath, under nitrogen protection, the raw materials 4-iodo-2,3-dimethyl-aniline d22-1 (5.1 g, 20.6 mmol) and TEA (4.1 g, 40.5 mmol) were dissolved in 10 mL of dichloromethane, and acetyl chloride (1.9 g, 24.7 mmol) was added. The mixture was reacted for 2 hours under an ice bath to stop the reaction. 50 mL of water was added to the reaction solution, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by flash reverse column chromatography (chromatographic column: C18; CH3CN / H2O, 10 / 7) to obtain a white solid d22-2 (5.5 g), with a yield of 92%. LCMS ESI-MS m / z: 290 [M+H] + .

[0404] Step 2: Under nitrogen protection, the intermediate d22-2 (1.5 g, 5.18 mmol) and the raw material methyl 2,2-difluoro-2-fluorosulfonylacetate d8-5 (4.9 g, 25.9 mmol) were dissolved in 15 mL DMF, and the catalyst CuI (1.4 g, 7.78 mmol) and HMPA (4.6 g, 25.9 mmol) were added. The mixture was heated to 80 ° C for 12 hours, the reaction was stopped, and filtered. 60 mL of water was added to the reaction solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by flash reverse column chromatography (chromatographic column: C18; CH3CN / H2O, 10 / 7) to obtain a yellow solid d22-3 (950 mg), yield: 79%. LCMS ESI-MS m / z: 232 [M+H] + .

[0405] Step 3: Dissolve the intermediate d22-3 (950 mg, 4.10 mmol) in 15 mL of ethanol, add dilute hydrochloric acid (7.6 mL, 6 M), heat the mixture to 80 ° C and react for 2 hours, then stop the reaction. Evaporate the solvent under reduced pressure to obtain a yellow solid d22 (750 mg), yield: 96%. LCMS ESI-MS m / z: 190 [M+H] + .

[0406] Preparation of intermediate d23

[0407]

[0408] Step 1: -78°C, under nitrogen protection, the raw material 4-bromo-2-fluoro-trifluoromethylbenzene d23-1 (2.1 g, 8.64 mmol) was dissolved in 21 mL of anhydrous tetrahydrofuran, and a hexane solution of LDA (6.5 mL, 2M) was added dropwise, and the mixture was stirred at this temperature for 1 hour. MeI (1.4 g, 9.51 mmol) was added to the reaction solution, and the temperature was raised to room temperature for reaction for 2 hours, and the reaction was stopped. 50 mL of saturated aqueous ammonium chloride solution was added to the reaction solution, extracted with dichloromethane, dried over anhydrous sodium sulfate, and concentrated to obtain a yellow oil d23-2 (1.5 g), with a yield of 68%. LCMS ESI-MS m / z: 257 [M+H] + .

[0409] Step 2: Under nitrogen protection, the intermediate d23-2 (550 mg, 2.14 mmol), Cs2CO3 (1.4 g, 4.28 mmol) and the raw material BocNH2 (275.8 mg, 2.35 mmol) were dissolved in 9 mL 1,4-dioxane, and the catalyst Pd2(dba)3 (58.8 mg, 0.064 mmol) and the ligand XantPhos (49.5 mg, 0.086 mmol) were added. The mixture was heated to 80 ° C for 1 hour, the reaction was stopped, and filtered. 60 mL of water was added to the reaction solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by flash reverse column chromatography (chromatographic column: C18;

[0410] CH3CN / H2O, 5 / 4) to give a yellow solid d23-3 (700 mg), yield: 95%. LCMS ESI-MS m / z: 294 [M+H] + .

[0411] Step 3: Dissolve the intermediate d23-3 (700 mg, 4.10 mmol) in 15 mL of HCl in 1,4-dioxane solution (2 M), react the mixture at room temperature for 1 hour, and stop the reaction. Evaporate the solvent under reduced pressure, add saturated NaHCO3 aqueous solution to the reaction solution to adjust the pH to about 8, extract with ethyl acetate, dry with anhydrous sodium sulfate, concentrate, and separate the crude product by flash reverse column chromatography (chromatographic column: C18; CH3CN / H2O, 10 / 7) to obtain a yellow solid d23 (300 mg), yield: 65%. LCMS ESI-MSm / z:194[M+H] + .

[0412] Preparation of intermediate d24

[0413]

[0414] Step 1: Under nitrogen protection, the raw material 3-fluoro-4-trifluoromethylaniline d24-1 (2.0 g, 11.2 mmol) was dissolved in 21 mL of acetic acid, and N-iodosuccinimide NIS (2.5 g, 11.2 mmol) was slowly added, and the mixture was reacted at room temperature for 3 hours. 50 mL of saturated aqueous ammonium chloride solution was added to the reaction solution, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by flash reverse column chromatography (chromatographic column: C18; CH3CN / H2O, 5 / 4) to obtain a yellow solid d24-2 (1.5 g), with a yield of 44%. LCMS ESI-MS m / z: 306 [M+H] + .

[0415] Step 2: Under nitrogen protection, the intermediate d24-2 (1.5 g, 4.92 mmol), K2CO3 (2.0 g, 14.8 mmol) and the raw material trimethylcyclotriboroxane d24-3 (930 mg, 7.38 mmol) were dissolved in 15 mL DME, and the catalyst Pd(PPh3)4 (0.28 g, 0.25 mmol) was added. The mixture was heated to 100 ° C for 1 hour, the reaction was stopped, and filtered. 60 mL of water was added to the reaction solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by flash reverse column chromatography (chromatographic column: C18; CH3CN / H2O, 5 / 3) to obtain a yellow oil d24 (300 mg), yield: 32%. LCMS ESI-MS m / z: 194 [M+H] + .

[0416] Example 1: Preparation of control molecule A3

[0417]

[0418] Steps: Under nitrogen protection, the intermediate c6 (50 mg, 0.07 mmol), the raw material A3-1 (25 mg, 0.11 mmol) and potassium phosphate (51 mg, 0.24 mmol) were dissolved in 1 mL of a mixed solution of 1,4-dioxane and water (v / v, 4 / 1), and the catalyst Pd(dppf)Cl2 (6.1 mg, 0.01 mmol) was added, and the temperature was raised to 100°C for 2 hours to stop the reaction. 5 mL of water was added to the reaction solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by TLC thin layer chromatography (DCM / MeOH=20 / 1) to obtain the target molecule A3 (10.1 mg), with a yield of 19%. LCMS ESI-MS m / z: 727 [M+H] + .

[0419] 1H NMR(400MHz,DMSO-d6)δ10.39(s,1H),10.22(s,1H),8.58(s,1H),8.47(s,1H),8.0 7(d,J=7.6Hz,1H),8.02(d,J=11.6Hz,1H),7.97(s,1H),7.72(d,J=8.0Hz,1H),6.53 (d,J=9.6Hz,1H),5.36(s,2H),3.53(s,3H),3.50–3.46(m,1H),3.04–2.94(m,3H), 3.30–3.15(m,3H),2.86–2.79(m,1H),2.68–2.62(m,1H),2.44(s,3H),1.23(s,3H).

[0420] Example 2: Preparation of target molecules P1-P2

[0421]

[0422] Step 1: Under nitrogen protection, intermediate a31 (2.86 g, 6.26 mmol), intermediate b2 (4.5 g, 17.86 mmol) and K3PO4 (13.3 g, 62.6 mmol) were dissolved in a mixed solution of 30 mL DMF and water (v / v, 6 / 1), and catalyst Pd(dppf)Cl2 (2.7 g, 3.76 mmol) was added. The temperature was raised to 80 ° C for 1 hour to stop the reaction. 200 mL of water was added to the reaction solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was washed with tetrahydrofuran to obtain a white solid P1-1 (662 mg), with a yield of 21%. LCMS ESI-MS m / z: 504 [M+H] + .

[0423] Step 2: Under nitrogen protection, the compound P1-1 (400 mg, 0.79 mmol) was dissolved in 8 mL DMF, N-bromosuccinimide NBS (283 mg, 1.58 mmol) was added, and the temperature was raised to 60°C for 1 hour to stop the reaction. 20 mL of water was added to the reaction solution, extracted with dichloromethane, dried over anhydrous sodium sulfate, and concentrated to obtain a white solid P1-2 (200 mg), with a yield of 43%. LCMS ESI-MS m / z: 582 [M+H] + .

[0424] Step 3: Under nitrogen protection, the compound P1-2 (66 mg, 0.11 mmol), the raw material P1-3 (70 mg, 0.23 mmol) and K3PO4 (73 mg, 0.34 mmol) were dissolved in 2 mL of n-butanol, and the catalyst XphosPdG3 (9.6 mg, 0.01 mmol) was added, and the temperature was raised to 90 ° C for 1 hour to stop the reaction. 5 mL of water was added to the reaction solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by flash reverse column chromatography (chromatographic column: C18; CH3CN / H2O=2 / 1; retention time: 11 min) to obtain a white solid P1-4 (75 mg), yield: 97%. LCMS ESI-MS m / z: 685 [M+H] + .

[0425] Step 4: Dissolve the compound P1-4 (100 mg, 0.15 mmol) in 1 mL of 1,4-dioxane solution (2 M) of hydrogen chloride, react at room temperature for 1 hour, and stop the reaction. Evaporate the solvent under reduced pressure to obtain a white solid P1-5 (62 mg), yield: 98%. LCMS ESI-MS m / z: 585 [M+H] + .

[0426] Step 5: Under nitrogen protection, the intermediate 5-hydroxy-6-methyl-pyrimidine-4-carboxylic acid b1 (23 mg, 0.15 mmol) and 1-chloro-N,N,2-trimethylpropyl-1-enyl-1-amine (40 mg, 0.30 mmol) were dissolved in 2 mL of dichloromethane and stirred at room temperature for 1 hour. DIEA (129 mg, 1.0 mmol) and the compound P1-5 (62 mg, 0.10 mmol) were added to the reaction solution, reacted at room temperature for 1 hour, and the reaction was stopped. 15 mL of water was added to the reaction solution, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by HPLC preparative chromatography (chromatographic column: Xbridge Prep OBD C18 Column, 30*150 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3+0.05% NH3 H2O; mobile phase B: acetonitrile; flow rate: 60 mL / min; retention time: 6.5 min) to obtain the target molecule P1 (1.4 mg), yield: 2%. LCMS ESI-MS m / z: 721 [M+H] + .

[0427] 1H NMR (300MHz, DMSO-d6) δ10.13(s,1H),8.55(s,1H),8.02(s,1H),7.71(d,J=8.5Hz,1H),7.63(s,1H),7.60–7.49(m,1H),5.85(s,1H),5. 40(s,2H),5.28(s,2H),4.90(d,J=3.8Hz,2H),4.70-3.70(s,4H),3.51(s,3H),2.74(s,2H),2.44(s,5H),1.21(dt,J=11.3,6.9Hz,3H).

[0428] Referring to the synthetic route of compound P1, similar raw materials / intermediates (such as intermediate a2, etc.) were used to synthesize the following target molecules:

[0429]

[0430] Example 3: Testing the activity of the molecules of the present invention on the hydrolysis of double-stranded DNA by WRN helicase (Table 1).

[0431] Prepare the working solution and buffer to be tested. The test compound is dissolved in DMSO and diluted 4 times (10μM final concentration as the starting concentration). Add 0.2μL of the test compound solution to a 384-well plate, add 10μL (2X) WRN enzyme solution, incubate in the dark for 30 minutes, add 10μL of substrate detection solution containing double-stranded DNA to start the reaction (DNA length 19bp, 3' and 5' labeled TAMRA and BHQ2 respectively), and incubate at room temperature for 60 minutes. Calculate the inhibitory activity (IC) of the WRN enzyme based on the changes in the fluorescence Ex530 / Em590 of the blank group (DMSO) and the compound group. 50 ).

[0432] Calculation formula: Y = lower platform signal + (upper platform signal - lower platform signal) / (1 + 10^((LogIC 50 -X) × Hill slope))

[0433] X: log value of compound concentration

[0434] Y: Inhibition rate (%)

[0435] Table 1. Inhibitory effects of compounds on the unwinding of WRN enzyme

[0436] Compound <![CDATA[WRN unwinding / IC 50 / nM]]> Compound <![CDATA[WRN unwinding / IC 50 / nM]]> P1 1.5 P2 <5

[0437] Unwinding

[0438] The above results show that the molecule of the present invention has a good inhibitory effect on WRN DNA unwinding, and is expected to achieve a better tumor inhibition effect by inhibiting the WRN helicase activity.

[0439] Example 4: Testing the anti-proliferative activity of the molecules of the present invention against MSI-H tumor cells

[0440] The proliferation of tumor cells with microsatellite instability MSI-H is sensitive to WRN inhibitors, while the proliferation of tumor cells with microsatellite stability MSS is insensitive to WRN inhibitors. By testing the activity of both, it is shown that the molecules of the present invention have an inhibitory and synthetic lethal effect on WRN at the cellular level.

[0441] MSI unstable SW48 colorectal cancer cells were cultured in RMI1640 medium containing 10% FBS and 1% penicillin-streptomycin, placed in a 37°C, 5% CO2 constant temperature incubator, and 40 μL of cell suspension was added to each well of a 384-well microplate. 40 nL of compounds of different concentrations were added to each well using Echo, and placed in a 37°C, 5% CO2 constant temperature incubator for 5 days. 40 μL of CTG solution (Promega, Cat No. G7573) was added to each well and placed in a 37°C, 5% CO2 constant temperature incubator incubated in the dark for 30 minutes. The luminescence value was read using an Envision multifunctional microplate reader (Perkin Elmer, catalog number Envision 2104). The light signal was proportional to the amount of ATP in the system, and the ATP content directly characterized the number of viable cells in the system.

[0442] IC 50 Value calculation:

[0443] Y = lower platform signal + (upper platform signal - lower platform signal) / (1 + 10^((LogIC 50 -X) × Hill slope))

[0444] X: log value of compound concentration

[0445] Y: Inhibition rate (%)

[0446] Table 2.1: 2D antiproliferative effects of compounds on MSI-H colorectal cancer SW48 cell line

[0447] Compound <![CDATA[SW48 / IC 50 / nM]]> Compound <![CDATA[SW48 / IC 50 / nM <!-- 43 -->]]> P1 99 A1 261 P2 120 A3 2002

[0448] ND = Not Tested

[0449] Referring to WO2022249060, the following control molecule A1 was synthesized,

[0450] Table 2.2: Antiproliferative value and IC of compound A1 on SW48 cells50 calculate

[0451] Concentration.[nM] Test 1 / inhibition rate (%) Test 2 / Inhibition rate (%) Average value / inhibition rate (%) 10000 100.9954 102.0219 101.5087 2500 99.8401 101.2267 100.5334 625 97.8908 96.9311 97.4109 156.25 -2.1399 14.9471 6.4036 39.0625 -12.6411 -11.1067 -11.8739 9.765625 0.0311 -8.0940 -4.0314 2.44140625 -13.8489 -8.9023 -11.3756 0.610351563 -2.3700 -2.2651 -2.3176 0.152587891 -13.1741 -5.6058 -9.3899 0.038146973 -1.9993 1.1876 -0.4058

[0452] Table 2.3: Antiproliferative value and IC of compound P1 on SW48 cells 50 calculate

[0453] Concentration.[nM] Test 1 / inhibition rate (%) Test 2 / Inhibition rate (%) Average value / inhibition rate (%) 10000 99.9568 99.2521 99.6044 2500 99.5134 100.4599 99.9866 625 100.9698 99.7968 100.3833 156.25 98.4069 98.1926 98.2998 39.0625 1.0784 9.6067 5.3425 9.765625 6.5183 -4.5117 1.0033 2.44140625 5.9002 13.7365 9.8183 0.610351563 0.2978 -5.9025 -2.8023 0.152587891 5.6041 3.8110 4.7076 0.038146973 6.2212 21.5102 13.8657

[0454] Table 2.4: Antiproliferative values ​​and IC values ​​of compound P2 on SW48 cells 50 calculate

[0455]

[0456]

[0457] The above results show that the molecule of the present invention has a good anti-proliferation effect on MSI-H tumor cells and is expected to achieve a better tumor inhibition effect by inhibiting the WRN helicase activity.

[0458] The above results also show that: the control molecule A1 has no inhibitory effect on SW48 cells at a concentration of 156 nM, while the molecules of the present invention such as P1, P2, etc. still have significant inhibitory effects (>90%) at 156 nM.

[0459] Example 5: Testing the anti-proliferative activity of the molecules of the present invention on MSS tumor cells.

[0460] The HT-29 colorectal cancer cells of MSS were cultured in McCoy's5A medium containing 10% FBS and 1% penicillin-streptomycin, placed in a 37°C, 5% CO2 constant temperature incubator, and 40 μL of cell suspension was added to each well of a 384-well microplate. 40 nL of compounds of different concentrations were added to each well using Echo, and placed in a 37°C, 5% CO2 constant temperature incubator for 5 days. 40 μL of CTG solution (Promega, Cat No. G7573) was added to each well and placed in a 37°C, 5% CO2 constant temperature incubator incubated in the dark for 30 minutes. The luminescence value was read using an Envision multifunctional microplate reader (Perkin Elmer, catalog number Envision 2104). The light signal was proportional to the amount of ATP in the system, and the ATP content directly characterized the number of viable cells in the system.

[0461] IC 50 Value calculation:

[0462] Y = lower platform signal + (upper platform signal - lower platform signal) / (1 + 10^((LogIC 50 -X) × Hill slope))

[0463] X: log value of compound concentration

[0464] Y: Inhibition rate (%)

[0465] Table 3: 2D antiproliferative effects of compounds on MSS colon cancer HT-29 cell line.

[0466] Compound <![CDATA[HT-29 / IC 50 / nM]]> Compound <![CDATA[HT-29 / IC 50 / nM]]> P1 >10000 P2 >10000

[0467] ND = Not Tested

[0468] The above results show that the molecule of the present invention has no inhibitory effect on MSS tumor cells, reflecting the high selectivity brought by the selective inhibition of WRN by the molecule of the present invention.

[0469] Example 6: Liver microsome stability test of the compound

[0470] Specifically, the compounds of the present invention were subjected to a liver microsome stability test. The compounds to be tested were co-incubated with liver microsomes of different species with or without the addition of NADPH. The final concentration of the compounds to be tested in the test system was 1 μM, the final concentration of NADPH was 1 mM, and the final concentration of liver microsomes was 0.5 mg / mL. The concentration of the compounds in the incubation supernatant at different time points within 60 minutes was detected and the pharmacokinetic parameters (such as the clearance rate Cl int ).

[0471] Tests have shown that the molecule of the present invention has good metabolic stability (especially in the human body).

Claims

1. A compound of formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof, and a mixture thereof: in, X and Y are each independently selected from CH or N, and at least one of X and Y is a N atom; Ring A is absent, or Ring A is selected from C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 5-10 membered heterocyclyl or C 6-10 Aryl; R1 is selected from 5-12 membered heteroaryl or 5-12 membered heterocyclyl, wherein R1 is optionally substituted by 1, 2, 3, 4 or 5 R x replace; Ring B is absent, or Ring B is selected from a 5-6 membered heteroaryl or a 5-7 membered heterocyclyl; R x Selected from H, D, halogen, NH2, CN, OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, -C(O)R a 、-C(O)OR a 、-OC(O)R a 、-C(O)NH-R a 、-NHC(O)-R a 、-(CH2) p -OR a 、-(CH2) p -C(O)R a 、-P(O)-(R a )2 or -S(O)2-R a , where R a Selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl or C 3-6 Cycloalkyl, p is selected from 0, 1, 2, 3 or 4; or, two R on the same atom x Together they form oxo or thio; R2 is selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 3-6 Cycloalkyl; R3 is selected from H, D, halogen, NH2, CN, OH, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy or C 3-6 Cycloalkyl, or two R3 on different carbon atoms are connected to form a bridged ring, or two R3 on the same carbon atom are connected to form a C 3-10 Cycloalkyl, 5-10 membered heteroaryl, C 3-10 Cycloalkyl or 3-10 membered heterocyclic group; R4 is selected from H, D, halogen, NH2, CN, OH, SF5, SCF3, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Alkylthio, C 3-10 Cycloalkyl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl or C 6-10 Aryl; R5 is selected from H, D, halogen, NH2, CN, OH, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 3-6 Cycloalkyl; m is selected from 0, 1, 2, 3, 4 or 5; n is selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8; Indicates a single bond or a double bond; R1-R5 may be optionally deuterated, up to fully deuterated.

2. The compound of claim 1, or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof, and a mixture thereof, wherein: X and Y are each independently selected from CH or N, and at least one of X and Y is a N atom; Ring A is absent or is selected from a 5-6 membered heteroaryl group, wherein the 5-6 membered heteroaryl group and the benzene ring to which it is connected together form the following heteroaryl group, The ring A is preferably absent; Ring B is absent, or Ring B is selected from a 5-6 membered heteroaryl or a 5-7 membered heterocyclyl; R1 is a 5-10 membered heteroaryl or a 5-12 membered heterocyclic group, preferably a 5-10 membered bicyclic heteroaryl group, wherein R1 is optionally replaced by 1, 2 or 3 R x replace; R x Preferably, H, NH2, CH3, CH2OH, CH2OCH3 or C(O)CH3 or -S(O)2-CH3, or two R on the same carbon atom x Together they form an oxo group; Preferably, R1 is selected from Ring B is absent or selected from C 3-10 Cycloalkyl, 5-10 membered heterocyclyl, 5-10 membered heteroaryl or C 6-10 Aryl, the ring B is optionally substituted by 1, 2, 3, 4 or 5 selected from halogen, C 1-6 Alkyl or C 1-6 Substitution of haloalkyl groups; Q and Q' are independently selected from CH or N, and at most one of Q and Q' is N; R y Selected from H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl; R2 is selected from C 1-4 Alkyl, such as CH3 or CH2CH3; R3 is selected from H, D or C 1-4 Alkyl, such as H, D or CH3, or two R3 on different carbon atoms are connected to form a bridged ring, or two R3 on the same carbon atom are connected to form a C 3-5 Cycloalkyl, such as cyclopropyl; R4 is selected from H, F, Cl, Br, CH3, CH2CH3, SCF3, OCF3, CF3 or pyridine; R5 is selected from H, CH3 or CD3, preferably H or CH3; R a Selected from C 1-6 Alkyl; m is selected from 0, 1, 2 or 3; k is selected from 0, 1, 2, 3, 4 or 5.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof, and a mixture thereof, wherein: R1 is selected from: in, represents a single bond or a double bond. When Q is N and ring B exists, represents a single bond; Q and Q' are independently selected from CH or N, and at most one of Q and Q' is N; Ring B is absent or selected from C 3-10 Cycloalkyl, 5-10 membered heterocyclyl, 5-10 membered heteroaryl or C 6-10 Aryl, the ring B is optionally substituted by 1, 2, 3, 4 or 5 selected from halogen, C 1-6 Alkyl or C 1-6 Substitution of haloalkyl groups; R x Selected from H, NH2, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -C(O)R a 、-C(O)OR a 、-OC(O)R a 、-C(O)NH-R a 、-NHC(O)-R a 、-(CH2) p -OR a or -(CH2) p -C(O)R a , where R a Selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl, p is selected from 1, 2 or 3; R y Selected from H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl; R a Selected from C 1-6 alkyl; m is selected from 0, 1, 2, 3, 4 or 5; k is selected from 0, 1, 2, 3, 4 or 5; Preferably, represents a single bond or a double bond. When Q is N and ring B exists, represents a single bond; Q and Q' are independently selected from CH or N, and at most one of Q and Q' is N; Ring B is absent or is selected from 5-7 membered heterocyclyl or 5-6 membered heteroaryl, and the ring B is optionally substituted by 1, 2 or 3 selected from halogen or C 1-4 Substitution of alkyl groups; R x Selected from H, NH2, C 1-4 Alkyl, -C(O)R a or -(CH2) p -OR a , where R a Select from H or C 1-4 Alkyl, p is selected from 1 or 2; R x Preferably H, NH2, CH3, CH2OH, CH2OCH3 or C(O)CH3; R y Selected from H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl; R a Selected from CH3; m is selected from 0, 1, 2 or 3; k is selected from 0, 1, 2 or 3; More preferably, R1 is selected from:

4. A compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof, and a mixture thereof, selected from the following structures: in, The variables are as defined in any one of claims 1-3.

5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof, and a mixture thereof, which has the structure of (II-1) or (III-1): in, R2 is selected from H, D, C 1-6 Alkyl, C 1-6 Alkoxy or C 1-6 Haloalkyl; R4 is selected from H, D, halogen, CN, SCF3, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 3-6 Cycloalkyl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl or C 6-10 Aryl; R5 is selected from H, D, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Alkoxy or C 1-6 Haloalkyl; m is selected from 0, 1, 2, 3, 4 or 5.

6. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof, and a mixture thereof, wherein: The compound has the structure of (IV-1) or (V-1): in, R 4a Selected from H, halogen, CN, C 1-6 Alkyl, C 1-6 Alkoxy or C 1-6 Haloalkyl; R 4b Selected from halogen, CN, C 1-6 Alkyl, C 1-6 Alkoxy or C 1-6 Haloalkyl; R 4d Selected from H, CN, halogen, C 1-6 Alkyl, C 1-6 Alkoxy or C 1-6 Halogenated alkyl.

7. A compound, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer thereof, wherein the compound is selected from:

8. A compound, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer thereof, wherein the compound is selected from:

9. Use of a compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof or a pharmaceutical composition according to claim 8 in the preparation of a medicament for treating and / or preventing a WRN-mediated disease.

10. The use of claim 9, wherein the WRN-mediated disease is cancer, and the cancer is selected from: gastric cancer, colorectal cancer, colon cancer, rectal cancer, large intestine adenocarcinoma, lung cancer, bronchial cancer, small cell lung cancer, non-small cell lung cancer, or pancreatic cancer.

Citation Information

Cited By

  • WRN inhibitors

    US12344609B2

  • WRN inhibitors

    US12421233B2

  • WRN inhibitors

    US12528806B2

  • Triazolopyrimidine derivative, preparation method therefor and use thereof

    WO2025152932A1

  • Spiro derivative serving as WRN inhibitor and use of spiro derivative

    WO2025161791A1